


RESEARCH ARTICLE

Deletion of lynx1 reduces the function of $\alpha 6^*$ nicotinic receptors

Rell L. Parker¹, Heidi C. O'Neill², Beverley M. Henley¹, Charles R. Wageman², Ryan M. Drenan³, Michael J. Marks^{2,4}, Julie M. Miwa⁵, Sharon R. Grady², Henry A. Lester¹

1 Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States of America, **2** Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO, United States of America, **3** Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America, **4** Department of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States of America, **5** Department of Biological Sciences, Lehigh University, Bethlehem, PA, United States of America



OPEN ACCESS

Citation: Parker RL, O'Neill HC, Henley BM, Wageman CR, Drenan RM, Marks MJ, et al. (2017) Deletion of lynx1 reduces the function of $\alpha 6^*$ nicotinic receptors. PLoS ONE 12(12): e0188715. <https://doi.org/10.1371/journal.pone.0188715>

Editor: Mohammed Akaaboune, University of Michigan, UNITED STATES

Received: June 14, 2017

Accepted: November 13, 2017

Published: December 5, 2017

Copyright: © 2017 Parker et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This research was supported by funds provided by California Tobacco-Related Diseases Research Program (<http://www.trdrp.org>), Grant 22DT-0008 to RLP, and 19KT-0032 to JMM. Additional support was provided by NIH / NIDA (<https://www.drugabuse.gov/>) grants, DA003194, DA012242, and P30-DA015663 to MJM, DA017279 to HAL, and DA019375 to HAL and MJM, DA030396 and DA035942 to RMD, and DA033831, DA032464 to JMM. The funders had

Abstract

The $\alpha 6$ nicotinic acetylcholine receptor (nAChR) subunit is an attractive drug target for treating nicotine addiction because it is present at limited sites in the brain including the reward pathway. Lynx1 modulates several nAChR subtypes; lynx1-nAChR interaction sites could possibly provide drug targets. We found that dopaminergic cells from the substantia nigra pars compacta (SNc) express lynx1 mRNA transcripts and, as assessed by co-immunoprecipitation, $\alpha 6$ receptors form stable complexes with lynx1 protein, although co-transfection with lynx1 did not affect nicotine-induced currents from cell lines transfected with $\alpha 6$ and $\beta 2$. To test whether lynx1 is important for the function of $\alpha 6$ nAChRs *in vivo*, we bred transgenic mice carrying a hypersensitive mutation in the $\alpha 6$ nAChR subunit ($\alpha 6L9^S$) with lynx1 knock-out mice, providing a selective probe of the effects of lynx1 on $\alpha 6^*$ nAChRs. Lynx1 removal reduced the $\alpha 6$ component of nicotine-mediated rubidium efflux and dopamine (DA) release from synaptosomal preparations with no effect on numbers of $\alpha 6\beta 2$ binding sites, indicating that lynx1 is functionally important for $\alpha 6^*$ nAChR activity. No effects of lynx1 removal were detected on nicotine-induced currents in slices from SNc, suggesting that lynx1 affects pre-synaptic $\alpha 6^*$ nAChR function more than somatic function. In the absence of agonist, lynx1 removal did not alter DA release in dorsal striatum as measured by fast scan cyclic voltammetry. Lynx1 removal affected some behaviors, including a novel-environment assay and nicotine-stimulated locomotion. Trends in 24-hour home-cage behavior were also suggestive of an effect of lynx1 removal. Conditioned place preference for nicotine was not affected by lynx1 removal. The results show that some functional and behavioral aspects of $\alpha 6$ -nAChRs are modulated by lynx1.

Introduction

Nicotinic acetylcholine receptors (nAChRs) are essential for many aspects of normal brain function, but their most important public health relevance is their role in nicotine addiction. Nicotine addiction causes approximately 12% of premature worldwide deaths in people over

no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

30 years of age (WHO Global Report: Mortality Attributable to Tobacco). This pervasive harm makes it imperative to find more effective methods of nicotine cessation. In the search for a pharmacological therapy to aid in nicotine cessation, one particular subclass of nAChRs, those containing the $\alpha 6$ subunit, has garnered intense interest as a drug target [1, 2]. Studies have shown that nAChRs containing the $\alpha 6$ subunit ($\alpha 6^*$ nAChRs) are necessary for the rewarding effects of nicotine [3–5]. The $\alpha 6^*$ nAChR is localized to the dopaminergic (DA) neurons of the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc), as well as neurons of the locus coeruleus, retinal ganglia, superior colliculi (SC) and medial habenula (MHb) [6–9]. This localization of $\alpha 6^*$ nAChR to just a few neuronal cell types suggests that drugs targeting this specific subtype would have fewer side effects than drugs targeting nAChRs with more widespread expression in brain [2, 3, 10]. Because of the difficulty of finding small molecule drugs that selectively target the $\alpha 6^*$ nAChR, it might be useful to investigate interactions of this receptor with other proteins. Such studies may identify other useful drug target sites.

Previous studies demonstrate that lynx1 is capable of modulating several classes of nicotinic receptors, including $\alpha 4\beta 2$ [11, 12], $\alpha 7$ [13–15] and $\alpha 3\beta 4(\alpha 5)$ [16] nAChR subtypes. Lynx1 can act as a brake on nicotinic receptor function by causing a shift to the right of concentration-response curves in $\alpha 4\beta 2$ nAChRs, shifting receptor subunit stoichiometry by affecting assembly in the endoplasmic reticulum [17], increasing the rate of desensitization and slowing the recovery from desensitization [11–13, 18], as well as influencing plasticity and spine dynamics [19]. However, no previous studies examined whether lynx1 produces effects on $\alpha 6^*$ nAChR function, although a water-soluble variant of lynx1 forms complexes with $\alpha 6^*$ nAChRs [20].

To facilitate studies of the $\alpha 6$ nicotinic receptor subunit in a mouse model, a hypersensitive mutation has been introduced in the pore lining M2 domain (L9'S mutation: the Leu 9' residue in the M2 domain was mutated to Ser)[21]. Mice containing the $\alpha 6L9'S$ mutation are BAC transgenic mice that express several copies of the $\alpha 6$ gene modified by a L9'S mutation [21]. This L9'S mutation produces hypersensitive receptors that are sensitive to lower nicotine concentrations, demonstrated with a shift to the left in dose-response relations [22–24]. This strategy of generating mice with hypersensitive nAChRs enables investigation of behavioral traits at nicotine doses that activate only the hypersensitive subtypes as well as more precise biochemical and physiological assays [23]. Mice with $\alpha 6L9'S$ nicotinic receptors exhibit several phenotypes resulting from over-activation of $\alpha 6^*$ nAChRs in DA neurons of the VTA and SNc, including locomotor hyperactivity and augmented DA release [21]. Several subsequent studies have used these mice to investigate the role of the $\alpha 6^*$ nAChR function *in vivo* [25–28]. For example, the $\alpha 4$ nAChR subunit was deleted from the $\alpha 6L9'S$ mice by cross breeding [27], with the resulting line of mice showing considerably attenuated effect of the hypersensitive mutation, indicating that the receptor subtype, $(\alpha 4\beta 2)(\alpha 6\beta 2)\beta 3$, is important for the expression of hyperactive phenotypes.

We chose to investigate whether lynx1 regulates $\alpha 6^*$ nAChR expression and function. For the current study, we used the $\alpha 6L9'S$ mice to determine whether deletion of lynx1 affects $\alpha 6^*$ nAChRs, either by reduction or augmentation of the known phenotypes of the $\alpha 6L9'S$ mice. We cross bred the two mouse lines, $\alpha 6L9'S$ and lynx1 null mutant (lynx1KO), and utilized biochemical approaches, along with electrophysiology and behavior in mice with both lynx1KO and $\alpha 6L9'S$ mutations to determine whether lynx1 regulates $\alpha 6^*$ nAChRs. We found effects of lynx1 on some $\alpha 6^*$ nAChR-mediated functional assays and on some mouse behaviors; and we found that lynx1 directly interacts with $\alpha 6^*$ nAChRs, providing a possible mechanistic basis for the functional and behavioral effects.

Results

Protein and mRNA levels and interactions

In order to test whether lynx1 interacts with $\alpha 6^*$ nicotinic receptors, we conducted a co-immunoprecipitation experiment using HEK-293 cells transfected with cDNA encoding nAChRs and lynx1. HEK-293 cells were transiently transfected with either $\alpha 4$ GFP or $\alpha 6$ YFP nicotinic subunits, plus $\beta 2$ WT nicotinic subunits, and lynx1. We used an anti-GFP antibody to pull down the $\alpha 6$ YFP or the $\alpha 4$ GFP fusion protein using conditions that retain stable protein complexes. Because GFP and YFP differ by only a few amino acids at regions distinct from epitopes, the two fluorophores are precipitated well by anti-GFP antibodies. We analyzed the immunoprecipitated nAChR complexes by western blot analysis using an anti-lynx1 antibody (Fig 1A). In material from cells transfected with lynx1 plus either $\alpha 4$ GFP and $\beta 2$ WT or $\alpha 6$ YFP and $\beta 2$ WT, we detected lynx1 on the blot, indicating that lynx1 forms a stable complex with $\alpha 4\beta 2$ and $\alpha 6\beta 2$ nAChRs. These data confirmed previous reports that lynx1 does immunoprecipitate with $\alpha 4\beta 2$ nicotinic receptors [11]. In control experiments, when either lynx1 or the nAChR subunits were omitted or the anti-GFP antibody was not added, no lynx1 was detected (Fig 1B). This indicates that lynx1 binds in a complex with $\alpha 6$ YFP $\beta 2$ receptors as well as with $\alpha 4$ GFP $\beta 2$ nAChRs.

We used RNA-Seq to confirm that lynx1 RNA transcript is present in the brain regions that are associated with $\alpha 6$ nicotinic receptors. SNc cells were identified by anatomical location in midbrain slices and pools of 20 cells were collected using laser capture microdissection and pooled ($n = 3$ pools). RNA-Seq was performed and the relative levels of lynx1, $\alpha 4$ (*Chrna4*), and $\alpha 6$ (*Chrna6*) were measured, in addition to tyrosine hydroxylase (*TH*), a gene highly and specifically expressed in DA neurons, which served as a positive control (Fig 1C). This shows that lynx1 is indeed present in DA neurons, along with $\alpha 6$ and $\alpha 4$ nAChR subunits. Because $> 90\%$ of DA neurons express $\alpha 6$ subunit protein [6], it is highly likely that lynx1 is present in the same SNc DA neurons as $\alpha 6$ subunits.

We next determined whether there is a functional significance to the interaction between lynx1 and $\alpha 6^*$ nAChRs. Wildtype $\alpha 6^*$ nAChRs have previously shown much weaker agonist-induced currents than other nAChR subtypes in most heterologous systems [29–32]. By transfecting $\alpha 6$ YFP and $\beta 2$ WT nicotinic receptor subunits with and without lynx1 in HEK293 cells, we tested whether addition of lynx1 would increase the surface expression and functional activity of $\alpha 6^*$ nicotinic receptors. Using whole cell patch clamp electrophysiology, responses to a puff of 300 μ M nicotine were recorded. Cells were selected for patching only if fluorescence was visually evident, suggesting that $\alpha 6$ YFP protein was present in the cell. In the case of transfection with $\alpha 6$ YFP + $\beta 2$, $n = 12$ cells were patched and puffed with nicotine. None showed a nicotine-induced current > 10 pA. When lynx1 was transfected in addition to $\alpha 6$ YFP $\beta 2$ WT, there was again little or no nicotine response. In this case, $n = 7$ cells were puffed with nicotine and none showed a response above 10 pA. Therefore, in HEK293 cells, lynx1 by itself does not appear to enable expression of functional $\alpha 6\beta 2$ -nAChRs.

N2a cells do express functional $\alpha 6\beta 2$ -nAChR on the surface with modest efficiency [32, 33]. Therefore, we used N2a cells to determine whether adding lynx1 changes the efficiency of functional $\alpha 6\beta 2$ -nAChR expression. In the case of $\alpha 6$ YFP $\beta 2$ WT, 8 of 10 cells exhibited a response to 300 μ M nicotine (average peak response = 22.0 ± 6.2 pA). When cells were transfected with $\alpha 6$ YFP $\beta 2$ WT + lynx1, 6 of 9 cells responded (23.9 ± 7.6 pA). Average traces are shown in Fig 2A. Adding lynx1 did not significantly affect the size of the response (Fig 2B) or the percentage of cells responding. The addition of lynx1 had no major effect on the response waveform.




Fig 1. A) Western blot of cells transfected with either $\alpha 4\text{GFP}$, $\beta 2$, and lynx1 (left two lanes) or $\alpha 6\text{YFP}$, $\beta 2$, and lynx1 (right two lanes) and subjected to immunoprecipitation. Input lanes (first and third lanes) are cell extracts. The immunoprecipitation was performed using protein A beads coated with anti-GFP antibody (termed anti-FP); the blot was performed with an anti-lynx1 antibody. B) Western blot of cells transfected with either $\alpha 6\text{YFP}$, $\beta 2$, and lynx1 (left 4 lanes), $\alpha 6\text{YFP}$ and $\beta 2$ without lynx1 1 (lanes 5 and 6), or lynx1 only

(right two lanes). In the 3rd and 4th lanes, no anti-GFP antibody was added to the immunoprecipitation extract. The blot was performed with an anti-lynx1 antibody. C) The lynx1 gene is expressed in DA neurons (in addition to *TH* (tyrosine hydroxylase), *Chrna6* ($\alpha 6$ nicotinic receptor), and *Chrna4* ($\alpha 4$ nicotinic receptor)). We collected and pooled 20 SNc neurons ($n = 3$ pools) using laser-capture microscopy, then assessed transcriptome-wide expression by RNA-Seq. Cufflinks was used to calculate the (FPKM) expression levels in laser captured SNc neurons. *TH* is expressed at 2615 ± 194.7 FPKM; *Lynx1* is expressed at 26.79 ± 7.12 , *Chrna6* is expressed at 71.67 ± 24.31 FPKM, and *Chrna4* is expressed at 41.67 ± 11.39 FPKM ($n = 3$ pools). These data are presented on a log10 scale. FPKM: fragments per kilobase per million mapped reads.

<https://doi.org/10.1371/journal.pone.0188715.g001>

Neurons *in vivo* have mechanisms for more efficient functional expression of various nAChRs; possibly these mechanisms are crucial for $\alpha 6^*$ nAChRs [6–8, 34]. Previous studies have used mice containing hypersensitive $\alpha 6^*$ nAChRs to isolate and amplify the $\alpha 6^*$ nAChR responses [21]. $\alpha 6^*$ receptors are expressed in the DA neurons and visual system axons, and the $\alpha 6L9'S$ mutation unmasks $\alpha 6^*$ nAChR function to varying degrees in those regions [21]. To study the effects of lynx1 on $\alpha 6^*$ nAChRs, we bred the $\alpha 6L9'S$ mice to lynx1KO mice [13, 21]. We hypothesized that the effects of lynx1 on the hypersensitive $\alpha 6^*$ nAChRs may resolve changes in $\alpha 6^*$ function resulting from lynx1KO.

To determine whether lynx1KO affected the quantity of nAChRs, we measured [125 I]epibatidine binding to membrane preparations from several brain regions of four genotypes of mice (lynx1 WT and KO on both $\alpha 6$ WT and $\alpha 6L9'S$ background). To assess changes in selected nAChRs subunit populations, we analyzed the amount of [125 I]epibatidine binding that was inhibited by the addition of α -conotoxin MII (α -CtxMII) (50 nM), which selectively blocks $\alpha 6\beta 2^*$ sites, or addition of a low concentration (50 nM) of cytisine, which selectively blocks the $\alpha 4\beta 2^*$ binding sites. Regions measured included striatum (ST), olfactory tubercle (OT), superior colliculus (SC), assayed for both sites, as well as frontal cortex (fCX), hippocampus (HP) and visual cortex (vCX) assayed for only $\alpha 4\beta 2$ sites. We assayed mice from each genotype; results are presented in Tables 1 and 2. Overall, little or no difference was seen when lynx1 was knocked out. No significant differences were found between lynx1WT and KO on either $\alpha 6$




Fig 2. A) Average whole-cell nicotine-induced currents (200 ms puffs, 300 μ M) from N2a cells transfected with either $\alpha 6YFP$ and $\beta 2$ (8 cells) or $\alpha 6YFP$, $\beta 2$, and lynx1 (6 cells). Scale is 1 s and 5 pA for both traces. B) Graph showing average peak response; error bars are SEM. Average response for $\alpha 6YFP$ and $\beta 2$ was 22.0 ± 6.2 pA and the average response for $\alpha 6YFP$, $\beta 2$, and lynx1 was 23.9 ± 7.6 pA. There was no significant effect of lynx1 addition.

<https://doi.org/10.1371/journal.pone.0188715.g002>

Table 1. $\alpha 6\beta 2$ binding sites in isolated membrane preparations.

	ST	OT	SC
	% of control		
lynx1WT/ $\alpha 6$ WT	100 $\pm$ 10.7 (n = 14)	100 $\pm$ 12.4 (n = 13)	100 $\pm$ 8.7 (n = 12)
lynx1KO/ $\alpha 6$ WT	130.1 $\pm$ 24.1 (n = 12)	105.4 $\pm$ 17.7 (n = 7)	114.2 $\pm$ 14.6 (n = 9)
lynx1WT/ $\alpha 6$ L9'S	115.9 $\pm$ 11.4 (n = 17)	94.4 $\pm$ 14.1 (n = 13)	75.0 $\pm$ 5.8 (n = 15)
lynx1KO/ $\alpha 6$ L9'S	84.7 $\pm$ 14.9 (n = 8)	104.6 $\pm$ 14.8 (n = 8)	61.8 $\pm$ 17.3 (n = 8)

Data expressed as % of lynx1WT/ $\alpha 6$ WT. Data were analyzed for effect of lynx1 on each $\alpha 6$ background for each region by t-test. No significant effects of the lynx1KO genotype were found.

<https://doi.org/10.1371/journal.pone.0188715.t001>

background in any region for $\alpha 6\beta 2^*$ binding sites. In ST, the lynx1KO compared to lynx1WT on the $\alpha 6$ WT background exhibited a modest but significant increase in $\alpha 4\beta 2$ binding sites of ~ 15% ($p < 0.05$). In SC, a modest but significant decrease (18%) in $\alpha 4\beta 2^*$ binding sites was noted for the lynx1KO compared to the lynx1WT on the $\alpha 6$ L9'S background ($p < 0.01$). No other differences were detected in any of the six regions for these sites.

To better assess the $\alpha 6\beta 2^*$ binding sites in small regions, we used quantitative autoradiography with [125 I]epibatidine, with and without 50 nM α -CtxMII in 10 brain regions from the lynx1WT and KO mice (n = 5–7 mice per group) on the $\alpha 6$ L9'S background. These data (Table 3) confirm that lynx1 has little or no effect on numbers of $\alpha 6\beta 2$ binding sites in $\alpha 6$ L9'S mice. Data presented in Table 4 show binding that was not inhibited by α -CtxMII, which represents mostly $\alpha 4\beta 2$ sites. No significant differences were found in any of the 10 regions assayed. Although epibatidine binding does not differentiate between surface and subcellular localization of nicotinic receptors, these data do indicate that, in general, nicotinic receptor expression is not affected by lynx1KO. Previous studies evaluating epibatidine binding in the $\alpha 6$ L9'S vs WT mice ST and OT have shown either no change in α -CtxMII-sensitive or -resistant binding in the ST or OT [27], or a slight increase in α -CtxMII-sensitive in OT and no change in α -CtxMII-resistant binding [21]. Because the epibatidine binding experiments have shown that neither the $\alpha 6$ L9'S nor the lynx1KO produced marked change in number of $\alpha 6\beta 2$ binding sites, we hypothesized that the lynx1KO x $\alpha 6$ L9'S mouse would be useful in analyzing effects of lynx1KO on the function of $\alpha 6^*$ receptors in the mouse brain.

Table 2. $\alpha 4\beta 2$ binding sites in isolated membrane preparations.

	ST	OT	SC	fCX	vCX	HP
	% of control					
lynx1WT/ $\alpha 6$ WT	100 $\pm$ 2.7 (n = 13)	100 $\pm$ 2.1 (n = 13)	100 $\pm$ 2.5 (n = 12)	100 $\pm$ 13.9 (n = 7)	100 $\pm$ 5.3 (n = 7)	100 $\pm$ 5.0 (n = 6)
lynx1KO/ $\alpha 6$ WT	115.1 $\pm$ 6.0* (n = 12)	103.9 $\pm$ 2.3 (n = 10)	106.8 $\pm$ 4.8 (n = 9)	101.8 $\pm$ 13.0 (n = 5)	108.8 $\pm$ 10.3 (n = 5)	116.9 $\pm$ 7.2 (n = 5)
lynx1WT/ $\alpha 6$ L9'S	110.9 $\pm$ 2.5 (n = 17)	111.3 $\pm$ 3.7 (n = 16)	103.7 $\pm$ 3.4 (n = 14)	101.7 $\pm$ 5.7 (n = 6)	97.9 $\pm$ 5.3 (n = 7)	111.0 $\pm$ 11.1 (n = 8)
lynx1KO/ $\alpha 6$ L9'S	115.3 $\pm$ 2.5 (n = 9)	111.7 $\pm$ 2.6 (n = 7)	85.4 $\pm$ 3.5** (n = 7)	114.8 $\pm$ 11.8 (n = 4)	100.0 $\pm$ 8.6 (n = 5)	131.4 $\pm$ 8.9 (n = 5)

Data expressed as % of lynx1WT/ $\alpha 6$ WT. Data analyzed for effects of lynx1 on each $\alpha 6$ background for each region by t-test. Significant effects of lynx1 are seen for ST for the lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT genotypes (* $P < 0.05$) and for SC with lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S (** $P < 0.01$).

<https://doi.org/10.1371/journal.pone.0188715.t002>

Table 3. $\alpha 6\beta 2$ binding sites by autoradiography.

	NAC	OT	ST	opt	OPN
	fmol of binding /mg wet weight of tissue				
lynx1WT/ $\alpha 6L9'S$	0.76 ± 0.25 (n = 6)	0.79 ± 0.16 (n = 6)	0.88 ± 0.19 (n = 6)	1.17 ± 0.44 (n = 6)	4.38 ± 0.52 (n = 6)
lynx1KO/ $\alpha 6L9'S$	1.22 ± 0.17 (n = 7)	1.02 ± 0.21 (n = 7)	0.91 ± 0.10 (n = 7)	1.47 ± 0.31 (n = 7)	4.29 ± 1.45 (n = 6)
	DLG	VLG	SN	VTA	SC
lynx1WT/ $\alpha 6L9'S$	5.15 ± 0.76 (n = 6)	4.42 ± 1.18 (n = 6)	1.58 ± 0.26 (n = 5)	3.06 ± 1.32 (n = 5)	5.41 ± 0.51 (n = 6)
lynx1KO/ $\alpha 6L9'S$	6.48 ± 1.88 (n = 6)	3.14 ± 1.49 (n = 6)	1.65 ± 0.42 (n = 5)	1.83 ± 1.09 (n = 5)	6.73 ± 1.48 (n = 7)

Data are expressed as fmol of binding /mg wet weight of tissue. Region abbreviations are: NAC, nucleus accumbens; OT, olfactory tubercle; ST, striatum; opt, optic tracts; OPN, olivary pretectal nucleus; DLG, dorsal lateral geniculate; VLG, ventral lateral geniculate; SN, substantia nigra; VTA, ventral tegmental area; SC superior colliculus. Data were analyzed for effect of lynx1 for each region by t-test. No significant effects of lynx1 were found.

<https://doi.org/10.1371/journal.pone.0188715.t003>

Functional measurements in several brain regions: $^{86}\text{Rb}^+$ efflux

To measure changes in the agonist-induced flux through nAChRs, we used $^{86}\text{Rb}^+$ efflux measurements in synaptosomal preparations from SC, HP, fCX and vCX. In the SC we observed a significant decrease in the α -CtxMII-sensitive $^{86}\text{Rb}^+$ efflux in lynx1KO/ $\alpha 6\text{WT}$ mice compared to lynx1WT/ $\alpha 6\text{WT}$ mice, as well as in the lynx1KO/ $\alpha 6L9'S$ mice compared to the lynx1WT/ $\alpha 6L9'S$ (Fig 3). No change was found for α -CtxMII-resistant nAChR function. These results suggest that there is less $\alpha 6^*$ receptor function on the surface of SC cells when lynx1 is absent in mice, either with wildtype $\alpha 6$ subunits or with the $\alpha 6L9'S$ mutation. We found no differences in HP, fCX or vCX (Table 5); these regions contain no measurable $\alpha 6^*$ -nAChRs. The decrease observed in $\alpha 6^*$ receptor function in SC indicates that lynx1 is necessary for normal level of function of $\alpha 6^*$ nicotinic receptors in this region. Perhaps fewer receptors are retained on the surface without lynx1, or an interaction of lynx1 with $\alpha 6\beta 2^*$ nAChRs facilitates function by changing ratios of subtypes containing $\alpha 6$ subunits.

Dopamine neurons: Functional and biochemical measurements

We performed three different measurements on DA neurons to characterize changes at the cellular and synaptic level. To probe possible changes due to lynx1 KO at the nerve terminals

Table 4. $\alpha 4\beta 2$ binding sites by autoradiography.

	NAC	OT	ST	opt	OPN
	fmol of binding /mg wet weight of tissue				
lynx1WT/ $\alpha 6L9'S$	2.59 ± 0.14 (n = 6)	2.15 ± 0.16 (n = 6)	3.49 ± 0.21 (n = 6)	2.97 ± 0.21 (n = 6)	7.60 ± 0.53 (n = 6)
lynx1KO/ $\alpha 6L9'S$	2.20 ± 0.22 (n = 7)	2.13 ± 0.17 (n = 7)	3.70 ± 0.43 (n = 7)	2.88 ± 0.24 (n = 7)	8.82 ± 0.82 (n = 6)
	DLG	VLG	SN	VTA	SC
lynx1WT/ $\alpha 6L9'S$	12.35 ± 0.98 (n = 6)	8.06 ± 0.35 (n = 6)	8.13 ± 0.26 (n = 5)	8.24 ± 0.67 (n = 5)	7.83 ± 0.39 (n = 6)
lynx1KO/ $\alpha 6L9'S$	12.05 ± 1.31 (n = 6)	8.91 ± 0.85 (n = 6)	8.31 ± 0.60 (n = 5)	8.06 ± 0.95 (n = 5)	7.44 ± 0.73 (n = 7)

Data are expressed as fmol of binding /mg wet weight of tissue. Region abbreviations are: NAC, nucleus accumbens; OT, olfactory tubercle; ST, striatum; opt, optic tracts; OPN, olivary pretectal nucleus; DLG, dorsal lateral geniculate; VLG, ventral lateral geniculate; SN, substantia nigra; VTA, ventral tegmental area; SC superior colliculus. Data were analyzed for effect of lynx1 for each region by t-test. No significant effects of lynx1 were found.

<https://doi.org/10.1371/journal.pone.0188715.t004>




Fig 3. $^{86}\text{Rb}^+$ efflux evoked by 3 μM nicotine in superior colliculus synaptosomal preparations. Animal numbers: lynx1WT/ $\alpha 6$ WT = 7, lynx1KO/ $\alpha 6$ WT = 7, lynx1WT/ $\alpha 6$ L9'S = 7, lynx1KO/ $\alpha 6$ L9'S = 5. Left panel: α -CtxMII-sensitive efflux, mediated via $\alpha 6\beta 2^*$ nicotinic receptor (total efflux, minus efflux in the presence of α -CtxMII). Lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT are significantly different ($p < 0.001$), designated by $\wedge$. Lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S are significantly different ($p = 0.005$), designated by $*$. Middle panel: α -CtxMII-resistant efflux, mediated by $\alpha 4\beta 2^*$ nicotinic receptors (efflux in the presence of α -CtxMII). There are no significant differences between lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT or between lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S. Right panel: total $^{86}\text{Rb}^+$ efflux in superior colliculus. Lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT are significantly different ($p = 0.032$), designated by $\wedge$. Lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S are significantly different ($p = 0.003$), designated by $*$.

<https://doi.org/10.1371/journal.pone.0188715.g003>

of DA neurons, synaptosomal preparations from ST and OT were used to measure nicotine-mediated DA release. Data for ST are shown in Fig 4A–4C, and data for OT are shown in Fig 4D–4F. Previous studies established that the $\alpha 6$ L9'S mice have a larger α -CtxMII-inhibited

Table 5. $^{86}\text{Rb}^+$ efflux from crude synaptosomal preparations of HP, vCX, and fCX, for each genotype.

[nicotine], μM	0.5 μM	50 μM	0.5 μM	50 μM
hippocampus (HP)	lynx1WT/ $\alpha 6$ WT	lynx1WT/ $\alpha 6$ WT	lynx1WT/ $\alpha 6$ L9'S	lynx1WT/ $\alpha 6$ L9'S
	1.34 $\pm$ 0.17 (7)	5.05 $\pm$ 0.24 (7)	1.72 $\pm$ 0.27 (6)	5.19 $\pm$ 0.49 (6)
	lynx1KO/ $\alpha 6$ WT	lynx1KO/ $\alpha 6$ WT	lynx1KO/ $\alpha 6$ L9'S	lynx1KO/ $\alpha 6$ L9'S
	1.39 $\pm$ 0.14 (5)	5.62 $\pm$ 0.73 (5)	0.95 $\pm$ 0.13 (5)	5.34 $\pm$ 0.53 (5)
visual cortex (vCX)	lynx1WT/ $\alpha 6$ WT	lynx1WT/ $\alpha 6$ WT	lynx1WT/ $\alpha 6$ L9'S	lynx1WT/ $\alpha 6$ L9'S
	1.65 $\pm$ 0.12 (7)	8.25 $\pm$ 0.46 (7)	1.58 $\pm$ 0.23 (6)	7.49 $\pm$ 0.72 (6)
	lynx1KO/ $\alpha 6$ WT	lynx1KO/ $\alpha 6$ WT	lynx1KO/ $\alpha 6$ L9'S	lynx1KO/ $\alpha 6$ L9'S
	1.46 $\pm$ 0.22 (5)	6.70 $\pm$ 0.62 (5)	1.56 $\pm$ 0.23 (5)	6.93 $\pm$ 0.72 (5)
frontal cortex (fCX)	lynx1WT/ $\alpha 6$ WT	lynx1WT/ $\alpha 6$ WT	lynx1WT/ $\alpha 6$ L9'S	lynx1WT/ $\alpha 6$ L9'S
	1.75 $\pm$ 0.25 (7)	6.84 $\pm$ 0.36 (7)	1.79 $\pm$ 0.12 (6)	7.38 $\pm$ 0.73 (6)
	lynx1WT/ $\alpha 6$ WT	lynx1WT/ $\alpha 6$ WT	lynx1WT/ $\alpha 6$ L9'S	lynx1WT/ $\alpha 6$ L9'S
	1.57 $\pm$ 0.30 (5)	6.77 $\pm$ 0.56 (5)	2.13 $\pm$ 0.35 (5)	6.65 $\pm$ 0.89 (5)

Data are normalized to baseline and given as mean $\pm$ sem (n). No significant differences among lynx1 or $\alpha 6$ genotypes were noted.

<https://doi.org/10.1371/journal.pone.0188715.t005>

component ($\alpha 6\beta 2^*$ nAChR) of nicotine-mediated DA release, with a complementary reduction of α -CtxMII-resistant ($\alpha 4\beta 2^*$ nAChR) nicotine-mediated DA release [21]. The $\alpha 6L9'S$ nicotine-mediated DA release concentration response curve is also shifted to the left: the synaptosomes are sensitive to lower concentrations of nicotine. In this set of experiments, the lynx1WT $\alpha 6L9'S$ mice results were similar to those reported previously for both ST and OT, showing increased α -CtxMII-sensitive activity ($\alpha 6\beta 2^*$) and decreased α -CtxMII-resistant activity ($\alpha 4\beta 2^*$). Notably, ST of the lynx1KO/ $\alpha 6L9'S$ mice showed an intermediate response, with lynx1KO/ $\alpha 6L9'S$ mice exhibiting a decreased proportion of α -CtxMII-sensitive receptor-mediated response (Fig 4B). This effect was less robust in OT and was not seen in either region with $\alpha 6$ WT mice. The absence of lynx1 had no detectable effect on the $\alpha 4\beta 2^*$ -mediated DA release in the ST or OT (Fig 4C and 4F). The reduction of $\alpha 6^*$ nicotinic receptor function in the absence of lynx1 in ST is similar to the pattern seen for SC $^{86}\text{Rb}^+$ efflux (Fig 3). However, unlike the SC pattern, the lynx1KO/ $\alpha 6$ WT were not different from lynx1WT/ $\alpha 6$ WT. These data indicate that the modulatory effect of lynx1 on $\alpha 6^*$ nicotinic receptor can influence DA release, but the altered pattern may indicate some difference in subunit composition of the $\alpha 6^*$ nAChR populations or the level of lynx1 influence in the regions assayed.

To assess function of $\alpha 6^*$ nAChR on the somata of DA neurons, in the presence and absence of lynx1, we recorded from the SNc of mouse brain slices. SNc DA neurons were identified, and a whole cell patch clamp configuration was obtained. We tested cells for I_h in voltage clamp and for firing patterns in current clamp to confirm that they were DA neurons [21]. DA cells were puffed with 1 and 10 μM nicotine (Fig 5A and 5B), at intervals of > 4 min to allow recovery from desensitization. For some cells, 100 nM α -CtxMII was perfused in the bath to block the $\alpha 6^*$ component of the nicotinic response (Fig 5C). We found no difference between lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT animals in the currents induced by 1 or 10 μM nicotine (Fig 5B). However, as previously published, the $\alpha 6L9'S$ mouse did show an increased response to nicotine compared to mice with wildtype $\alpha 6$ nAChRs [21]. Lynx1 deletion in lynx1KO did not affect the size of the response to nicotine in the $\alpha 6L9'S$ mice (Fig 5B). Adding α -CtxMII to the bath blocked most of the response in the lynx1WT/ $\alpha 6L9'S$ and the lynx1KO/ $\alpha 6L9'S$ animals (Fig 5C). There was no significant difference in the fractional block by α -CtxMII in the lynx1KO/ $\alpha 6L9'S$ and the lynx1WT/ $\alpha 6L9'S$ (Fig 5D). This indicates that lynx1 removal does not affect the percentage of the signal contributed by $\alpha 6^*$ nAChRs in SNc.

As an additional method of assessing function at DA terminals, we performed fast scan cyclic voltammetry (FSCV) experiments in the dorsal striatum (Fig 5E). Previous studies indicate that $\alpha 6L9'S$ mouse has altered DA release measured in the dorsal striatum [25, 27]. However, lynx1KO did not affect the electrically-stimulated DA release. We measured DA release in the lynx1WT/ $\alpha 6L9'S$ and lynx1KO/ $\alpha 6L9'S$ mice using single pulse (1p), 2 pulse (2p) or 4 pulse (4p) stimulations at 100 Hz. We also measured the α -CtxMII sensitivity of the 1p stimulation using bath application of 100 nM α -CtxMII. Average traces and the average peak responses are shown in Fig 5E and 5F. We also compared the ratio of 4p:1p peak response (Fig 4F), and there were no significant differences when lynx1 was deleted. For the lynx1WT/ $\alpha 6L9'S$ the ratio of 4p:1p was 2.12 ± 0.13 , and for the lynx1KO/ $\alpha 6L9'S$ the ratio of 4p:1p was 2.02 ± 0.13 . To compare the rate of DA uptake we fitted a single exponential decay to each waveform. There was no difference in the decay rate constant (τ) in the lynx1KO slices. Thus, in response to electrical stimulation, FSCV measurements reveal that the lynx1WT/ $\alpha 6L9'S$ mice and the lynx1KO/ $\alpha 6L9'S$ animals have similar peak DA release and τ .

The three DA neuron-based functional and biochemical measurements thus provide a mixed picture of lynx1 KO effects. In DA terminals of ST, we found decreased $\alpha 6^*$ specific nicotine-mediated DA release in lynx1KO/ $\alpha 6L9'S$ mice compared to lynx1WT/ $\alpha 6L9'S$ mice (Fig 4B). However, in SNc somata, deletion of lynx1 did not change nicotine-induced currents (Fig




Fig 4. Nicotine-induced DA release from synaptosomal preparations. Animal numbers: lynx1WT/ $\alpha 6\text{WT}$ = 6, lynx1KO/ $\alpha 6\text{WT}$ = 4, lynx1WT/ $\alpha 6\text{L9'S}$ = 7, lynx1KO/ $\alpha 6\text{L9'S}$ = 4. A) Total nicotine-induced DA release from striatal (ST) synaptosomes. Lynx1WT/ $\alpha 6\text{WT}$ and lynx1KO/ $\alpha 6\text{WT}$ differ significantly at 0.01 μM nicotine ($p = 0.031$), designated by $\wedge$. Lynx1WT/ $\alpha 6\text{L9'S}$ and lynx1KO/ $\alpha 6\text{L9'S}$ differ significantly at 1 μM ($p = 0.023$) and 10 μM ($p = 0.024$) nicotine, designated by *. B) $\alpha\text{-CtxMII}$ -sensitive nicotine-mediated DA release from ST synaptosomes. Lynx1WT/ $\alpha 6\text{WT}$ and lynx1KO/ $\alpha 6\text{WT}$ differ significantly at 1 μM nicotine ($p = 0.015$). Lynx1WT/ $\alpha 6\text{L9'S}$ and lynx1KO/ $\alpha 6\text{L9'S}$ differ significantly at 1 μM ($p = 0.022$) and 10 μM ($p = 0.042$) nicotine. C) $\alpha\text{-CtxMII}$ -resistant nicotine-mediated DA release from ST synaptosomes. There were no significant differences between lynx1WT/ $\alpha 6\text{WT}$ and lynx1KO/ $\alpha 6\text{WT}$ or between lynx1WT/ $\alpha 6\text{L9'S}$ and lynx1KO/ $\alpha 6\text{L9'S}$. D) Total nicotine-mediated DA release from olfactory tubercle (OT) synaptosomes. Lynx1WT/ $\alpha 6\text{WT}$ and lynx1KO/ $\alpha 6\text{WT}$ are not significantly different from each other. lynx1WT/ $\alpha 6\text{L9'S}$ and lynx1KO/ $\alpha 6\text{L9'S}$ differ significantly at 1 μM nicotine ($p = 0.042$). E) $\alpha\text{-CtxMII}$ -sensitive nicotine-mediated DA release from OT synaptosomes. Lynx1WT/ $\alpha 6\text{WT}$ and lynx1KO/ $\alpha 6\text{WT}$ do not differ significantly. Lynx1WT/ $\alpha 6\text{L9'S}$ and lynx1KO/ $\alpha 6\text{L9'S}$ differ significantly at 1 μM nicotine ($p = 0.010$). F) $\alpha\text{-CtxMII}$ -resistant nicotine-mediated DA release from OT synaptosomes. There were no significant differences between lynx1WT/ $\alpha 6\text{WT}$ and lynx1KO/ $\alpha 6\text{WT}$ or between lynx1WT/ $\alpha 6\text{L9'S}$ and lynx1KO/ $\alpha 6\text{L9'S}$.

<https://doi.org/10.1371/journal.pone.0188715.g004>

5A and 5B). In the absence of nicotine, we found no effects of lynx1 KO on electrically stimulated DA release using FSCV. Possible reasons for these differences may include processes that differ at the DA terminals vs the cell body. It is known that there are differences in the percentage of $\alpha 6^*$ receptors that reach the plasma membrane in terminals versus the cell body [1, 35], and effects of lynx1 removal may differentially affect the organelles in these regions [17]. Furthermore, the DA-release studies performed in striatal synaptosomes were evoked by nicotine and were concentration-dependent, whereas the FSCV studies were performed in the absence of exogenous ligand using electrical stimulation at 100Hz. Under the latter conditions, multiple processes may occur and the resulting DA release may be modified by some of these other effects of electrical stimulation. Therefore, it is unsurprising that detection of the effects of lynx1 on function of DA neurons, and on the role of their $\alpha 6^*$ nAChRs, depends on the method used and on other conditions of the assay.




Fig 5. A) Representative whole-cell nicotine-induced currents from SNc of lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S mouse brain slices (puffs of 10 μ M nicotine). Left is lynx1WT/ $\alpha 6$ L9'S; right is lynx1KO/ $\alpha 6$ L9'S. The scale is 2 s and 50 pA. B) Average peak currents induced by 1 and 10 μ M nicotine, including lynx1WT/ $\alpha 6$ WT, lynx1KO/ $\alpha 6$ WT, lynx1WT/ $\alpha 6$ L9'S, and lynx1KO/ $\alpha 6$ L9'S mice. Values for 1 μ M nicotine: lynx1WT/ $\alpha 6$ WT 13.6 $\pm$ 2.7 pA (7 cells), lynx1KO/ $\alpha 6$ WT 11.8 $\pm$ 1.4 pA (5 cells), lynx1WT/ $\alpha 6$ L9'S 208.5 $\pm$ 41.3 pA (11 cells), lynx1KO/ $\alpha 6$ L9'S 193.2 $\pm$ 34.4 pA (15 cells). Values for 10 μ M nicotine: lynx1WT/ $\alpha 6$ WT 31.7 $\pm$ 5.9 pA (7 cells), lynx1KO/ $\alpha 6$ WT 30.2 $\pm$ 7.5 pA (5 cells), lynx1WT/ $\alpha 6$ L9'S 358.5 $\pm$ 31.6 pA (12 cells), lynx1KO/ $\alpha 6$ L9'S 363.5 $\pm$ 30.4 (17 cells). No significant differences were found between lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT or between lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S. C) Currents induced by 1 μ M nicotine puffs before and after application of α -CtxMII. Response to 1 μ M nicotine is black trace; red trace is 5 minutes after starting the flow of 100 μ M α -CtxMII; blue trace is after 10 minutes of α -CtxMII. The left panel is lynx1WT/ $\alpha 6$ L9'S; the right panel is lynx1KO/ $\alpha 6$ L9'S. The scale is 2 s and 50 pA. D) Average fraction of signal remaining after application of 100 μ M α -CtxMII. For lynx1WT/ $\alpha 6$ L9'S the percent remaining is 0.08 $\pm$ 0.03% (2 cells). For lynx1KO/ $\alpha 6$ L9'S the percent remaining is 0.10 $\pm$ 0.02% (3 cells). There is no significant difference between the two genotypes. E) Average DA release in response to various stimulations, as measured with FSCV. The left panel is lynx1WT/ $\alpha 6$ L9'S; the right panel is lynx1KO/ $\alpha 6$ L9'S. The scale is 0.1 μ M DA. F) Average peak DA response. The values for lynx1WT/ $\alpha 6$ L9'S in μ M DA are for 1p 0.38 $\pm$ 0.05, for 2p 0.47 $\pm$ 0.04, for 4p 0.79 $\pm$ 0.08, and for 1p + α -CtxMII 0.10 $\pm$ 0.02. The values for lynx1KO/ $\alpha 6$ L9'S in μ M DA are for 1p 0.53 $\pm$ 0.11, for 2p 0.76 $\pm$ 0.16, for 4p 1.05 $\pm$ 0.22, and for 1p + α -CtxMII 0.13 $\pm$ 0.04. For the lynx1WT/ $\alpha 6$ L9'S the ratio of 4p:1p was 2.12 $\pm$ 0.13 and for the lynx1KO/ $\alpha 6$ L9'S the ratio of 4p:1p was 2.02 $\pm$ 0.13. For lynx1WT/ $\alpha 6$ L9'S there were 4 animals, 6 recording sites, except for the α -CtxMII studies that used 2 sites in 2 different animals. For lynx1KO/ $\alpha 6$ L9'S there were 5 animals, 9 recording sites, except for the α -CtxMII studies that used 4 sites in 4 different animals. There were no significant differences between the two genotypes.

<https://doi.org/10.1371/journal.pone.0188715.g005>

Nicotine-independent locomotor behavior

Next, we evaluated behavioral phenotypes to determine whether lynx1KO had effects on behaviors seen in $\alpha 6$ L9'S mice. The $\alpha 6$ L9'S behaviors include striking hyperactivity, with some mice running 2–10 km in a 24 h period [21, 27, 36]. We first tested habituation during the first 33 min in a novel environment. Fig 6A shows ambulations during this period. All the mice showed initially higher activity peaking at 2–3 min. As expected the lynx1WT/ $\alpha 6$ L9'S mice do not habituate appreciably. Of note, removal of lynx1 from the hyperactive mice significantly decreased their activity during minutes 4–9 ($p = 0.026$) and minutes 28–33 ($p = 0.043$) (Fig 6B). Lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT were significantly different from each other during minutes 4–9 only ($p = 0.006$) (Fig 6B).

In addition to the inability to habituate to a novel environment, some lynx1WT/ $\alpha 6$ L9'S mice are hyperactive during their active (dark) period [21, 27]. This occurs in 35–60% of animals of both sexes [21, 27]. We analyzed video recordings to ascertain the distance each mouse traveled during a 24-h home cage trial (Fig 6C). If hyperactivity is defined as movement greater than 1000 m in a 24-h period, 2 of 17 (12%) lynx1WT/ $\alpha 6$ WT mice and 1 of 17 (6%) lynx1KO/ $\alpha 6$ WT were hyperactive in this test, whereas, 14 of 24 (58.3%) of lynx1WT/ $\alpha 6$ L9'S mice in this cohort were hyperactive while 7 of 20 (35%) lynx1KO/ $\alpha 6$ L9'S showed hyperactivity. Using a more stringent cutoff of travelling 3000 m per 24-h period, 1 of 17 (6%) lynx1WT/ $\alpha 6$ WT mice and 0 of 17 (0%) lynx1KO/ $\alpha 6$ WT mice were hyperactive, while 9 of 24 (37.5%) lynx1WT/ $\alpha 6$ L9'S mice and only 3 of 20 (15%) lynx1KO/ $\alpha 6$ L9'S mice showed hyperactivity. Because there are two discrete populations and there is a low frequency in one of the groups, we applied Fisher's exact test to determine whether lynx1KO was a factor in these differences on the L9'S background for night-time activity. The p -value was 0.14 for a cutoff of 1000, and 0.17 for a cutoff of 3000; these were not statistically significant differences. Activity behaviors in $\alpha 6$ L9'S mice are not completely penetrant; only some of the mice exhibit the hyperactive behavior [21, 27, 36]. This wide phenotypic variation may have reduced the statistical power of our 24-h ambulation experiments, preventing detection of potentially subtle changes in ambulation caused by the lynx1KO. It is appropriate to remark that the trends for decreased activity with lynx1KO were in the same direction as the significant changes seen for habituation as well as in functional assays in synaptosomal preparations.

Nicotine-dependent behavior

Since a main question of this study was to determine whether lynx1KO might have effects on $\alpha 6^*$ nAChRs in the context of nicotine addiction, we tested whether nicotine had specific effects on lynx1KO animals. Previous studies in the $\alpha 6$ L9'S mice established that these mice are hyperactive in response to a single dose of nicotine, with the largest response occurring for an injection of 0.15 mg/kg nicotine (free base) [21]. We injected the four groups of mice with nicotine (0.15 mg/kg, ip) at minute 8 and measured their response by ambulation (Fig 7A and 7B). We calculated a pre-nicotine baseline for each mouse as the mean ambulatory counts per minute from minutes 3 to 5, and a peak response to nicotine from minutes 14–16. Acute nicotine administration had little effect in either lynx1WT/ $\alpha 6$ WT (11.7 ± 2.6 ambulatory counts before nicotine vs 21.6 ± 9.1 peak counts after nicotine, $t = 1.05$, $n = 15$, ns) or lynx1KO/ $\alpha 6$ WT mice (13.0 ± 1.2 before vs 11.4 ± 4.0 after, $t = 0.41$, $n = 15$, ns). On the $\alpha 6$ L9'S background the lynx1WT mice strongly responded to nicotine (13.7 ± 1.8 before vs 54.5 ± 12.1 after, $t = 3.30$, $n = 16$, $p < 0.01$). The lynx1KO/ $\alpha 6$ L9'S mice also showed significant response to nicotine (10.5 ± 1.2 counts before vs 34.6 ± 5.6 counts after, $t = 4.20$, $n = 18$, $p < 0.001$). A comparison of the two $\alpha 6$ L9'S genotypes by t -test yields $t = 1.50$ with dof of 32, not statistically different.




Fig 6. A) Response of mice to novel environment indicated by ambulation counts. Mice were placed in novel cages and their movement was measured by infrared beam breaks. Animal numbers: 20 lynx1WT/ $\alpha 6WT$, 18 lynx1KO/ $\alpha 6WT$, 24 lynx1WT/ $\alpha 6L9'S$, 14 lynx1KO/ $\alpha 6L9'S$. B) Sum of ambulation counts, with the experiment divided into 6 min bins to compare the ambulation during the beginning, middle, and end of the experiment. For lynx1WT/ $\alpha 6WT$ the values are: min 4–9 66.7 ± 3.2 counts, min 16–21 57.5 ± 4.1 counts, min 28–33 64.1 ± 6 counts. For lynx1KO/ $\alpha 6WT$ the values are: min 4–9 82.2 ± 4.4 counts, min 16–21 68.4 ± 4.7 counts, min 28–33 62.1 ± 5.9 counts. lynx1WT/ $\alpha 6WT$ and lynx1KO/ $\alpha 6WT$ were significantly different from each other in minutes 4–9 ($p = 0.006$). For lynx1WT/ $\alpha 6L9'S$ the values are: min 4–9 101.3 ± 12.6 counts, min 16–21 119.6 ± 20.6 counts, min 28–33 170.8 ± 30.0 counts. For lynx1KO/ $\alpha 6L9'S$ the values are: min 4–9 60.8 ± 7.3 counts, min 16–21 77.1 ± 10.0 counts, min 28–33 80.6 ± 22.0 counts. Lynx1WT/ $\alpha 6L9'S$ and lynx1KO/ $\alpha 6L9'S$ were significantly different from each other in min 4–9 ($p = 0.026$) and minutes 28–33 ($p = 0.043$). C) Total distance traveled over 24 h, as measured by automated mouse

behavior analysis (AMBA). Animal numbers: 17 lynx1WT/ $\alpha 6$ WT, 17 lynx1KO/ $\alpha 6$ WT, 24 lynx1WT/ $\alpha 6$ L9'S, and 20 lynx1KO/ $\alpha 6$ L9'S. No statistical significance was found between lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT, or between lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S.

<https://doi.org/10.1371/journal.pone.0188715.g006>




Fig 7. A) Response to a single injection of 0.15 mg/kg of nicotine. Animals were given a single IP injection of nicotine between minutes 8 and 9 of the experiment, and then their ambulations were measured until minute 43 of the experiment. Animal numbers: 15 lynx1WT/ $\alpha 6$ WT, 15 lynx1KO/ $\alpha 6$ WT, 16 lynx1WT/ $\alpha 6$ L9'S, 18 lynx1KO/ $\alpha 6$ L9'S. B) First-order exponential decay curves fitted to data for $\alpha 6$ L9'S genotypes following nicotine injection. The lynx1KO significantly decreased peak counts (p value = <0.001) compared to lynx1WT without affecting time constant of decay. C) Average change in preference for mice undergoing CPP protocol with dose of 0.03 mg/kg of nicotine. Animal numbers: 10 lynx1WT/ $\alpha 6$ L9'S, 14 lynx1KO/ $\alpha 6$ L9'S, 12 lynx1WT/ $\alpha 6$ WT, 16 lynx1KO/ $\alpha 6$ WT. Both lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S genotypes showed a statistically significant response to nicotine (p value = 0.042 and <0.001 , respectively, using a paired t -test). However, lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S were not significantly different from each other. The lynx1WT/ $\alpha 6$ WT and lynx1KO/ $\alpha 6$ WT genotypes did not show a significant CPP response, and were also not statistically different from each other.

<https://doi.org/10.1371/journal.pone.0188715.g007>

Within this dataset, there were two groups of behavioral responses to acute nicotine injection. There were mice showing little response and those that became hyperactive in response to nicotine. Both types of responses were observed in all genotypes and both sexes, similar to the pattern noted for home cage activity. While relatively few mice with the $\alpha 6$ WT background displayed locomotor activation calculated as a response of twice baseline, (3/15, 20% of lynx1WT/ $\alpha 6$ WT and 1/15, 7% of lynx1KO/ $\alpha 6$ WT), many mice on the $\alpha 6$ L9'S background showed activation (10/16, 63% of lynx1WT/ $\alpha 6$ L9'S and 11/18, 61% of lynx1KO/ $\alpha 6$ L9'S). Comparison of peak activity for the responders on the $\alpha 6$ L9'S background was 80.6 ± 13.6 counts for lynx1WT/ $\alpha 6$ L9'S ($n = 10$) and 50.9 ± 4.2 for the lynx1KO/ $\alpha 6$ L9'S group ($n = 11$) resulting in $t = 2.08$, a non-significant difference.

While the above analysis is complicated by the incomplete penetrance of the behavior in the $\alpha 6$ L9'S genotypes, the lynx1 KO does have a strong tendency to decrease the response to nicotine in the responding group. Analyzing the data as first-order exponential decay curves allows all data points to be used, rather than just the peak 3 minutes, resulting in more statistical power (Fig 7B). This analysis provides two parameters, maximal response and a first-order rate of decay. For all the mice, we calculated parameters for maximal response of 53.4 ± 1.6 counts for lynx1WT/ $\alpha 6$ L9'S ($n = 16$) and 40.4 ± 1.2 for lynx1KO/ $\alpha 6$ L9'S ($n = 18$) with rate constants of $0.048 \pm 0.003 \text{ min}^{-1}$ and $0.048 \pm 0.003 \text{ min}^{-1}$, respectively. The lynx1KO significantly decreased the peak counts ($t = 6.50$, $p < 0.001$) with no effect on rate of decay. For the responders only, analysis of the entire time course yielded maximal responses of 79.4 ± 2.5 counts for the lynx1WT/ $\alpha 6$ L9'S ($n = 10$) and 59.1 ± 2.2 for lynx1KO/ $\alpha 6$ L9'S ($n = 11$) ($t = 6.10$, $p < 0.001$) with first-order rate constants of $0.052 \pm 0.003 \text{ min}^{-1}$ and $0.056 \pm 0.004 \text{ min}^{-1}$, respectively. Thus, while effects of the lynx1 deletion for the $\alpha 6$ L9'S mice on ambulatory activity as mean counts/min in the peak 3 min for either the total population ($t = 1.50$, $\text{dof} = 32$) or the subset showing locomotor activation ($t = 2.08$, $\text{dof} = 19$) were not statistically significant, the effects of the lynx1KO for decreasing activity were highly significant when the complete data sets were analyzed by curve-fitting, as described here and above. The $\alpha 6$ WT genotypes both had insignificant activation (see above), vitiating curve fits for these two genotypes.

Next, we asked whether lynx1 removal affects nicotine-mediated reward behavior as measured by conditioned place preference (CPP) (Fig 7C). We used a nicotine dose of 0.03 mg/kg, and we found that the lynx1WT/ $\alpha 6$ L9'S mice exhibited significant CPP with this dose of nicotine, as expected from results previously found for another nicotinic agonist [37]. Additionally, the lynx1KO/ $\alpha 6$ L9'S mice showed significant CPP with this dose of nicotine ($p < 0.001$ with paired t-test); however, no significant difference was found between lynx1WT/ $\alpha 6$ L9'S and lynx1KO/ $\alpha 6$ L9'S mice. Neither of the genotypes that lacked the $\alpha 6$ L9'S mutation (lynx1WT/ $\alpha 6$ WT or lynx1KO/ $\alpha 6$ WT) developed CPP at this dose of nicotine. These results show that there is an effect of including the $\alpha 6$ L9'S subunit in the genome, but no effect of lynx1 removal. Therefore it appears that lynx1 does not produce significant effects on this measure of nicotine-mediated reward via $\alpha 6^*$ nAChRs.

Discussion

The data presented here show that the effects of removing lynx1 on $\alpha 6^*$ nAChRs are detectable but subtle, influencing $\alpha 6^*$ nAChR activity, DA release, and some locomotor behaviors. Lynx1 can associate with $\alpha 6$ YFP $\beta 2$ when transiently overexpressed in cell lines (Fig 1), but the addition of lynx1 did not affect the response to nicotine in transfected cells (Fig 2). Because functional studies in neurons may be more appropriate than in clonal cell lines, we subsequently used the lynx1KO and $\alpha 6$ L9'S mouse models to study the effects of lynx1 on $\alpha 6^*$ nAChR. Since these receptors are normally present in only a few brain regions, we studied whether those brain regions exhibited any changes when lynx1 was deleted.

As the Introduction notes, the strategy of generating mice with hypersensitive nAChRs enables investigation of behavioral traits at nicotine doses that activate only the hypersensitive subtypes as well as more precise biochemical and physiological assays. Previously, the hypersensitive mouse strategy has been applied to $\alpha 2^*$ -, $\alpha 4^*$ -, $\alpha 6^*$ -, $\alpha 7^*$ -, and $\alpha 9^*$ -nAChRs via M2 mutations in these α subunits, and has allowed researchers to assign nicotine-induced behavioral, biochemical, and physiological phenotypes to these nAChR subtypes [23]. However, one should note that quantitative aspects of our conclusions depend to some extent on the high levels of $\alpha 6^*$ nAChR activity in the $\alpha 6L9'S$ mice.

In synaptosomal preparations from mice, we discerned that lynx1KO reduced the amount of $^{86}\text{Rb}^+$ efflux in the SC that was mediated through $\alpha 6^*$ nAChRs, suggesting that there were fewer or functionally altered nAChRs when lynx1 was absent. These data indicate that lynx1 is necessary for the normal function of $\alpha 6^*$ nAChRs. This decrease in activity of $\alpha 6^*$ nAChRs was detectable in $\alpha 6\text{WT}$ only in SC. However, in the $\alpha 6L9'S$ mice with a larger $\alpha 6$ component, the nicotine-induced DA release in ST and OT as well as the $^{86}\text{Rb}^+$ efflux in SC all followed this pattern. In addition to these biochemical measures, absence of lynx1 decreases the ambulation of the $\alpha 6L9'S$ mice in a novel environment, as well as activation in response to an injection of nicotine. Our binding data provide evidence that the lynx1-induced changes may not be simply a decrease in $\alpha 6^*$ nAChR numbers as no changes were seen in numbers of $\alpha 6\beta 2$ binding sites across 10 regions. Binding data include both surface-expressed sites and intracellular sites, so it is possible that lynx1 changes the ratio between these two classes. Further, there might be lynx1-induced alteration in the relative numbers of subtypes of $\alpha 6^*$ nicotinic receptors. It has been shown that in the absence of the $\alpha 4$ subunit, the $\alpha 6^*$ mediated DA release as well as the hyperactive behavior of $\alpha 6L9'S$ mice is decreased [27]. The $(\alpha 4/\beta 2)(\alpha 6L9'S/\beta 2)(\beta 3)$ form of nicotinic receptors (where / denotes an agonist-binding interface) is absent in these less active $\alpha 4\text{KO}/\alpha 6L9'S$ mice [27]. Therefore, instead of changing numbers of surface-expressed $\alpha 6^*$ nicotinic receptors, lynx1 could function by decreasing the ratio of $(\alpha 4/\beta 2)(\alpha 6L9'S/\beta 2)(\beta 3)$ to $(\alpha 6L9'S/\beta 2)_2(\beta 3)$. It has been shown that lynx1 can alter the ratio of stoichiometries of $\alpha 4\beta 2^*$ nicotinic receptors [17].

Neither patch-clamp electrophysiology of DA neurons in the SNc, nor FSCV in slices of the striatum detected any effect of lynx1 removal, while Rb^+ efflux in SC and DA release in ST and OT (both synaptosomal preparations) did show effects of lynx1 on function of $\alpha 6^*$ nicotinic receptors. There are several possible explanations for this apparent inconsistency. In comparing the SNc to the striatum (sites of patch clamp vs synaptosomal DA release), lynx1 may have differential effects on nicotinic receptors that are localized on the cell body versus the terminals of these neurons [35]. Additionally, lynx1 may be necessary for normal targeting of the $\alpha 6^*$ nAChRs to the DA terminals, causing differences in the terminals that are undetectable when recordings are done from the cell bodies. To try to address the possibility of differences between the terminals and cell bodies, we used FSCV in the dorsal striatum as an alternative measure of DA release. In agreement with previously published data, we measured a significant increase in the size of the response from 1p to 4p in lynx1WT/ $\alpha 6L9'S$ compared to lynx1WT/ $\alpha 6\text{WT}$ mice [25]. The addition of α -CtxMII reduced DA release by ~ 90% in lynx1WT/ $\alpha 6L9'S$, far greater than previous reports in WT mice, but consistent with previous reports in the $\alpha 6L9'S$ mice [25]. However, we measured no differences between lynx1KO/ $\alpha 6L9'S$ mice and lynx1WT/ $\alpha 6L9'S$ mice in the presence of α -CtxMII. While both the FSCV and synaptosomal DA release experiments were conducted using striatal tissues, the FSCV is electrically stimulated, while the synaptosome experiments measured nicotine-induced release. Electrical stimulation activates multiple transmitter systems that contribute to the sum of the DA release response, while nicotine activates only nAChRs, possibly leading to different results. The synaptosomal nicotine-evoked DA release is also concentration-dependent. If

lynx1 has changed the ratio of subtypes of $\alpha 6^*$ nAChRs, a functional change would be more readily measured by concentration-response assays, where differences among receptor subtypes with altered potency and efficacy may be detected.

Previous studies have shown that lynx1 acts as a brake or a negative modulator of some nicotinic receptor subtypes, including $\alpha 4\beta 2$, $\alpha 3\beta 4$, $\alpha 5\alpha 3\beta 4$, and $\alpha 7$ nAChRs [11–13, 16]. However, the present data present a contrasting case with $\alpha 6^*$ nAChRs: lynx1 normally augments the function of $\alpha 6^*$ nAChRs, and removing lynx1 actually dampens the activity of both $\alpha 6$ and $\alpha 6L9'S$ nAChRs. This was unexpected and indicates that the $\alpha 6$ nAChR subunit likely has an atypical interaction with lynx1, perhaps like the lynx1 paralog Ly6g6e which increases $\alpha 4\beta 2$ responses [38]. Most of the significant effects of lynx1 KO on $\alpha 6^*$ nAChRs were measured using the $\alpha 6L9'S$ mutation which could indicate some difference in the interaction of lynx1 with $\alpha 6WT$ vs $\alpha 6L9'S$. However, in the SC a significant effect in the same direction was seen with $\alpha 6WT$.

Another unanticipated finding was the lack of effect of lynx1 on non- $\alpha 6^*$ nAChRs in the brain regions currently under investigation. Based on previous findings, lynx1 removal might be expected to have effects in the α -CtxMII-resistant populations of nicotinic receptors in the DA neurons, which include $\alpha 4\beta 2$ and $\alpha 5\alpha 4\beta 2$ [7, 39]. However, we observed no effects of lynx1 on α -CtxMII-resistant populations, in synaptosomal preparations, electrophysiology, or FSCV experiments. The $\alpha 4\beta 2^*$ nAChR population of DA neurons is highly enriched for the $\alpha 5\alpha 4\beta 2$ subtype [40]. If the major effect of lynx1 on $\alpha 4\beta 2^*$ is to selectively decrease the “high-sensitivity” or HS form, $(\alpha 4\beta 2)_2\beta 2$ [17], the population in DA terminals with large amounts of another HS form, $(\alpha 4\beta 2)_2\alpha 5$, could be less affected by lynx1. With current techniques, it is not possible to distinguish between functions of the two HS forms in striatal samples. In addition, the DA release assay used here measures only the HS forms of $\alpha 4\beta 2^*$ nicotinic receptor, and therefore would not detect any changes in “low-sensitivity” forms.

Many tobacco dependent people find smoking rewarding, and decoupling reward from dependence will be an important variable in smoking cessation strategies. The lynx1WT/ $\alpha 6L9'S$ mice show CPP, a reward-related behavior, at strikingly low doses of agonist [37], but full dose-response relations for CPP have not been studied in this strain. The present experiments were performed at one nicotine dose, 0.03 mg/kg, and showed robust CPP with no effects of lynx1 deletion. It remains possible that lower doses of nicotine would reveal an effect of lynx1 deletion.

In summary, we have found that $\alpha 6^*$ nAChRs are modulated by lynx1. This represents a new aspect of regulation for this subclass of nicotinic receptors. While we found no connection between lynx1 and nicotine CPP at the nicotine dose used, the finding that lynx1 modulates $\alpha 6^*$ nAChR-dependent locomotor activity and neurotransmitter release may be helpful in understanding some aspects of addiction to smoking. Further, since $\alpha 6^*$ nAChRs are involved in both motor function and reward, our understanding of the selective functional and behavioral actions of lynx on $\alpha 6^*$ nAChRs could be useful for addressing motor abnormalities and dyskinesias, without risk of confounding abuse liabilities.

Materials and methods

Cell culture, western blot, and co-immunoprecipitation

HEK293 and Neuro2a (N2a) cells were obtained from ATCC and were maintained with DMEM, Na pyruvate, Pen Strep antibiotics (Thermo Fisher), and 10% FBS (HEK293) or 45% DMEM, 45% Optimem, 10% FBS, and Pen Strep antibiotics (N2a). Cells were transfected using ExpressFect (Denville Scientific) and plasmids pCI-neo- $\alpha 4GFP$, pCI-neo- $\alpha 6YFP$, pCI-neo- $\beta 2WT$, and pc-DNA3.1-lynx1. For the co-immunoprecipitation, HEK293 cells were

transfected; 48 h post transfection, cells were harvested by scraping with PBS, followed by centrifugation for 4 minutes at 4000 rpm (1300 x g) (Eppendorf 5415C, Hauppauge, NY). Cells were lysed using ice-cold extraction buffer (50 mM Tris pH 7.4, 50 mM NaCl, 1% NP40, 1 mM EDTA, 1 mM EGTA, supplemented with 1% P8340, and 4 mM PMSF). The cells were triturated by pipetting 20–30 times in the extraction buffer and then allowed rest on ice for 5–10 min. Following that, they were centrifuged at 14,000 rpm (16,000 x g) (Eppendorf 5415C, Hauppauge, NY) for 5 min at 4°C. The supernatant was transferred to a new tube; 50 μ l was set aside for the input lane.

To bind the antibody to the protein A Dynabeads (Invitrogen, Carlsbad, CA; cat # 11122), 5 μ g of antibody was diluted into 200 μ l PBS with 0.02% Tween-20, mixed with 50 μ l of beads for 20 minutes at room temperature and then washed once with PBS containing 0.02% Tween-20. The cell supernatant was mixed with the antibody bound beads for 1 h at room temperature. Subsequently, the beads were washed 3x with PBS, then heated to 70°C for 10 minutes in 20 μ l of 1x Laemmli buffer (Bio-Rad Laboratories, Hercules, CA).

The samples were loaded onto a 4–10% gradient gel (Bio-Rad) and electrophoresed for 1.5 h at 100 V. The protein was transferred to nitrocellulose membrane using a semi-dry transfer system for 15 min at 15 V. The membrane was blocked with 5% milk for 1 h, then probed with primary goat anti-lynx1 antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) at 1:500 in 5% milk overnight at 4°C or rabbit anti-GFP (Invitrogen) antibody at 1:500 overnight. The secondary antibodies used were goat anti-rabbit at 1:5000 for one h and donkey anti-goat at 1:2000 for two h. Western blots were imaged either using anti-HRP secondary antibodies and film, or using fluorescent secondary antibodies and a LI-COR (Lincoln, NE 68504) Odyssey imaging system.

Cell electrophysiology

Cells were maintained and transfected as described above, but for electrophysiology they were plated at a lower density onto glass coverslips. 48 h post-transfection, the cells were transferred to the 32°C recording chamber, where they were perfused with oxygenated (95% O₂ / 5% CO₂) ACSF. The ACSF consists of (in mM): 124 NaCl, 3 KCl, 1.25 NaH₂PO₄, 26 NaHCO₃, 10 glucose, 1.3 MgSO₄, and 2.5 CaCl₂ [41]. Cells were visualized with an Hg lamp to determine which had been transfected with $\alpha 6$ GFP, and a whole cell patch clamp configuration was obtained. Cells were puffed with nicotine for 200 ms using a Picospritzer (Parker Hannafin)

Animals

All animal experiments were conducted in accordance with the *Guide for Care and Use of Laboratory Animals*, and protocols were approved by the Institutional Animal Care and Use Committee at Caltech (Protocol 1386–13) or the University of Colorado at Boulder. Mice used for experiments were generated from breeding pairs where both parents were heterozygous for the lynx1KO allele and one of the parents had the BAC transgene containing the $\alpha 6$ L9'S mutation from line 2 (copy number 18.9±0.9, Cohen et al, 2012) [13, 21]. Animals were group housed, except for immediately before and during behavioral experiments. The animals had free access to food and water and were on a 13 h dark: 11 h light cycle. When conditions allowed, mice were used for novel environment experiments, then AMBA, and finally for single injection of nicotine. Mice of both sexes were studied. We noted no marked differences between males and females; therefore we conducted no systematic studies on this point.

RNA-Seq materials and methods

For laser capture microdissection, C57BL6/DBA WT mice were deeply anesthetized with sodium pentobarbital (100 mg/kg; i.p.) and sacrificed by decapitation. Our methods pipeline

for fabricating cDNA libraries via laser capture microdissection, and performing RNA-Seq were previously described [42]. Briefly, whole brains from 4 month old male mice ($n = 3$) were collected (post-mortem interval of < 5 min), fresh frozen over dry ice, and stored at -80°C . Midbrain cryostat [43] sections ($20\ \mu\text{m}$) were mounted on UV-treated Zeiss Membrane Slides (1.0 PEN NF), air dried for 5 minutes, and stained with cresyl violet for 1 minute. The sections were rinsed, dried and then visualized under brightfield illumination at 400X magnification on a Zeiss PALM Laser Capture Micro Dissection microscope. Twenty putative DA⁺ cell bodies from the SNc were dissected using multiple low laser energy pulses, and were catapulted into Zeiss 200 μL adhesive caps. Cell lysis solution (Illumina, San Diego, CA) containing 3' SMART reverse transcription primers and quantitation controls ("spikes") were then added into the pool of cells prior to freezing.

To fabricate cDNA libraries, we prepared amplified cDNA from RNA, using Clontech's SMARTer™ Ultra Low RNA system for Illumina Sequencing (Clontech, Mountain View, CA) as previously described [44]. Poly(A)⁺ RNA was reverse transcribed through oligo dT priming to generate full-length cDNA, which was then amplified using 22 cycles, using Clontech's Advantage 2 PCR system. RNA-Seq libraries were constructed using the Nextera DNA Sample Prep kit (Illumina). cDNA was "tagmented" at 55°C with Nextera transposase, and tagmented DNA was purified using Agencourt AMPure XP beads (Beckman Coulter Genomics). Purified DNA was amplified using five cycles of Nextera PCR. After quality control measures of yield and fragment length distribution were taken using the Qubit fluorometer (Invitrogen, Carlsbad, CA) and the Agilent (Santa Clara, CA) Bioanalyzer, 50 bp or 100 bp sequencing reads were generated on the Illumina HiSeq instrument. Each sequencing library generated > 20 million uniquely mapping reads.

For computational analysis, 50 bp or 100 bp sequence tags were mapped to the mouse genome using TopHat 1.3.2 [45]. We quantified transcript abundance (FPKM: fragments per kilobase per million mapped reads (expression values)) using Cufflinks. We annotated the transcripts with genome annotations provided by ENSEMBL. Data were analyzed and graphs were generated using GraphPad Prism 5.

Rubidium efflux

Previously described methods [46] were used to measure $^{86}\text{Rb}^{+}$ efflux from synaptosomal preparations of mouse brain regions using carrier-free $^{86}\text{RbCl}$ purchased from Perkin Elmer Life Sciences (Boston, MA). Aliquots of the synaptosomal preparation, loaded with $^{86}\text{Rb}^{+}$, were superfused at 2.5 ml/min. A 5-s exposure to nicotine stimulated efflux; sample effluent was pumped through a 200 μL flow-through Cherenkov cell in a β -RAM Radioactivity HPLC detector (IN/US Systems, Inc., Tampa, FL) allowing continuous monitoring. Stimulated levels of $^{86}\text{Rb}^{+}$ efflux as units were determined as evoked cpm exceeding baseline level of efflux, summed and normalized to baseline level.

DA release

Previously described methods [27] were followed using 7,8- ^{3}H]DA (20–40 Ci/mmol) obtained from Perkin Elmer Life Sciences (Boston, MA). Crude synaptosomal preparations from freshly dissected brain regions were allowed to take up tracer ^{3}H]DA prior to superfusion at 0.7 ml/min for 10 min. Release of DA was stimulated by exposure to nicotine for 20s. Parallel aliquots were exposed to 50 nM α -conotoxin MII (α -CtxMII) (generously provided by Dr. J. Michael McIntosh, University of Utah) for 5 min before the nicotine exposure. Fractions (10 s, ~ 0.1 ml) were collected into 96-well plates using an FC204 fraction collector (Gilson, Inc., Middleton, WI) for 3.8 min starting one min before nicotine exposure. DA release units

are calculated as evoked cpm exceeding baseline cpm, summed and normalized to baseline cpm.

Membrane binding

Membrane binding experiments were conducted on tissue remaining from synaptosomal experiments after a lysis step and further washing by resuspension and centrifugation using the methods of Whiteaker et al. [8]. [125 I]epibatidine (2200 Ci/mmol purchased from Perkin Elmer Life Sciences (Boston, MA)) was used at 200 pM with a 2 h incubation at room temperature. Additions to parallel samples included 50 nM cytosine (to isolate the cytosine-sensitive population in 6 brain regions), 50 nM α -CtxMII (to isolate the α -CtxMII-sensitive population in 3 brain regions) or 100 μ M nicotine for blank determination. Data are calculated as fmol bound/ mg protein and expressed as % of lynx1WT/ $\alpha 6$ WT genotype.

Autoradiography

For binding experiments using autoradiography, published methods were followed [8, 47, 48]. [125 I]epibatidine with unlabeled 6-I-epibatidine (kindly donated by Dr Kenneth Kellar, Georgetown University) (total 200 pM) with or without α CtxMII (50 nM) was used to determine levels of nicotinic receptor with and without $\alpha 6\beta 2$ sites. [125 I]epibatidine with and without cytosine (50 nM) was used to determine $\alpha 4\beta 2$ sites. Blanks were equal to film background. After incubation (4 h, rt), washing and drying steps, slides were exposed to Packard Super Resolution Cyclone Storage Phosphor Screens (Perkin Elmer Life Sciences, Boston, MA) for subsequent quantitation compared to tissue paste standards using Optiquant software (Perkin Elmer Life Sciences). Ten brain regions known to express both sites were quantitated for the Lynx1WT and KO on the $\alpha 6L9/S$ genotype. Data are expressed as cpm/mg wet lynx1WT/ $\alpha 6$ WT.

Slice electrophysiology

Mice used for midbrain recordings were ages P17 to P25. All animals were genotyped before and after the experiment (animal numbers: 11 lynx1WT/ $\alpha 6L9/S$, 13 lynx1KO/ $\alpha 6L9/S$, 8 lynx1WT/ $\alpha 6$ WT, 8 lynx1KO/ $\alpha 6$ WT). Animals are euthanized with CO₂ gas, then subjected to cardiac perfusion with an oxygenated (95% O₂ / 5% CO₂) ice-cold glycerol-substituted ACSF (in mM: 250 glycerol, 2.5 KCl, 1.2 NaH₂PO₄, 26 NaHCO₃, 11 glucose, 1.3 MgCl₂, and 2.4 CaCl₂). Each animal was then decapitated; the brain dissected and mounted on a vibratome in ice-cold glycerol ACSF. 250 μ M coronal sections were made using a vibratome (DTK-1000; Ted Pella, Redding, CA). Slices were allowed to recover for 1 h in regular ACSF bubbled with 95% O₂ / 5% CO₂ at 32°C, then warmed to room temperature. The ACSF consisted of (in mM): 124 NaCl, 3 KCl, 1.25 NaH₂PO₄, 26 NaHCO₃, 10 glucose, 1.3 MgSO₄, and 2.5 CaCl₂ [41]. After 15 min at room temperature the slices were put into fresh room temperature ACSF. Recordings were made in a chamber perfused with ACSF at 32°C, bubbled with 95% O₂ / 5% CO₂, at a rate of 1–2 mL/min. The internal pipette solution in mM consisted of 135 K gluconate, 5 EGTA, 10 HEPES, 2 MgCl₂, 0.5 CaCl₂, 3 Mg-ATP, and 0.2 GTP. The slices were visualized with an upright microscope (BX50WI, Olympus) and near-infrared illumination. Recordings were made from the VTA or SNc, and a picture was taken of each cell recorded from to verify location. We tested for I_h and measured the firing rate in each cell to determine that we were indeed recording from a DA neuron. Patch pipettes were made using a programmable microelectrode puller (P-87; Sutter Instrument Co., Novato, CA) and pipette resistances were 4–8 M Ω . Recordings were made with an Axon Multiclamp 700A Amplifier and recorded using Clampex 10, both from Molecular Devices Axon (Sunnyvale, CA). Data were sampled at

5 kHz and low-pass filtered at 2 kHz. The holding potential was -65 mV. Over a period of 1.4 s, the puffer pipette was moved to within one cell length of the cell by a piezoelectric controller (Burleigh Instruments; Fishers Park, NY). There was a 100 ms pause; a puff of 200 ms drug was applied using a picospritzer; and then the puffer pipette was retracted over 360 ms. Data were analyzed using Clampfit 10, also from Molecular Devices.

Fast-scan cyclic voltammetry (FSCV)

Electrodes were fabricated using carbon fiber (7 μ M, unsized from Goodfellow) and glass without a filament from Sutter. One carbon fiber was pulled through a glass micropipette. This was then pulled into two electrodes on a Sutter P-87 puller. The carbon fibers were trimmed, and the electrodes dipped into epoxy for 7 min and then quickly rinsed in acetone. Electrodes were baked overnight at 80°C to cure the epoxy. The carbon fiber was trimmed to an appropriate length just before use. The carbon fiber was placed in the dorsal striatum, just below the surface of the slice. The animals used in these experiments were 18–27 weeks old (Animal numbers: 10 lynx1WT/ $\alpha 6$ L9'S, 7 lynx1KO/ $\alpha 6$ L9'S). Slices were prepared as for electrophysiology, except the slices were 300 μ M thick and were taken from the striatum. Recordings were made with an Axon Multiclamp 700B Amplifier and recorded using Clampex 9, both from Molecular Devices Axon (Sunnyvale, CA). Voltage ramps of 20 ms duration were applied to the carbon fiber at 100 ms intervals (sampling interval 20 μ s). After the current waveform stabilized, a pulse was applied to an adjacent region of the dorsal striatum using a bipolar stimulating electrode (FHC). The pulse was sufficient to elicit maximal stimulation, and the 2p and 4p stimuli were delivered at 100 Hz. The peak response was measured, and a single exponential fit was used to determine tau. See [49, 50]. The electrodes were calibrated at the end of each experiment with 1 μ M DA.

Spontaneous activity in novel environment

Mice used in the study of locomotion were eight to sixteen weeks old by the beginning of the experiment. Horizontal locomotor activity was measured with an infrared photobeam activity cage system (San Diego Instruments; San Diego, CA). Ambulation events were recorded when two neighboring photobeams were broken in succession. Mice were moved to the room immediately before the experiment and put into fresh cages at the start of the novel environment test. Their activity was measured for 33 min. Mice were returned to their home cages following the experimental period (Animal numbers: 24 lynx1WT/ $\alpha 6$ L9'S, 14 lynx1KO/ $\alpha 6$ L9'S, 20 lynx1WT/ $\alpha 6$ WT, 18 lynx1KO/ $\alpha 6$ WT).

Automated mouse behavior analysis (AMBA)

Video-based software analysis of home cage behavior was conducted as described previously [27, 51]. Mice that were normally group housed were singly caged and habituated to the video recording room for 24 h before recording (animal numbers: 24 lynx1WT/ $\alpha 6$ L9'S, 20 lynx1KO/ $\alpha 6$ L9'S, 17 lynx1WT/ $\alpha 6$ WT, and 17 lynx1KO/ $\alpha 6$ WT). The video recording began the following day (2 h before the dark phase) and continued for 23.5–24.0 h, using dim red lights for recording during the dark phase. The videos were analyzed using the definitions and settings described in HomeCageScan 3.0 software (CleverSys).

Locomotion in response to nicotine injections

Acute locomotor activity in response to nicotine was measured by recording ambulation events for 43 min. This was recorded with the same equipment as the spontaneous activity

assay. Groups of eight mice were singly housed in clean cages and their baseline level of activity was recorded for eight min (animal numbers: 16 lynx1WT/ $\alpha 6$ L9'S, 18 lynx1KO/ $\alpha 6$ L9'S, 15 lynx1WT/ $\alpha 6$ WT, 15 lynx1KO/ $\alpha 6$ WT). Mice were removed from their cage, injected with nicotine 0.15 mg/kg intraperitoneally and returned to the cage within 30 sec.

Conditioned place preference (CPP)

The conditioned place preference test apparatus consists of a three-chamber rectangular cage with a center neutral gray compartment (Med Associates, Inc., St. Albans, VT). One test compartment is black with a stainless-steel grid rod floor. The second test chamber is white with a square stainless-steel mesh floor. Guillotine doors separate the chambers and can be fixed in the closed or opened position (Animal numbers: 10 lynx1WT/ $\alpha 6$ L9'S, 14 lynx1KO/ $\alpha 6$ L9'S, 12 lynx1WT/ $\alpha 6$ WT, 16 lynx1KO/ $\alpha 6$ WT).

The day before the test, the animals are moved into the room with the CPP apparatus and singly housed in clean cages. The CPP protocol was a 10-day experiment. On day one (pre-test day) a mouse was placed in the central compartment and allowed free access to all chambers. The time spent in each chamber was recorded over a 20 min period. Days 2–9 were training days. Intraperitoneal injections of nicotine free base (0.03 mg/kg) were paired with one of the conditioning chambers, while injections of saline are paired with the other. In a biased design, mice received nicotine in the less preferred chamber as determined on day one of the experiment. Conditioning trials for the nicotine-associated chamber occurred on days 2, 4, 6, and 8; conditioning trials for the saline-associated chamber occurred on days 3, 5, 7, and 9. Each training trial lasted 20 min. On the last day (post-test) of the experiment, the mouse was once again given free access to all chambers for 20 min. The time spent in each chamber during the pre-test was subtracted from the time spent in each chamber on the post-test day. A preference toward the nicotine-associated chamber compared to baseline is a measure of the reward behavior associated with nicotine [22].

Statistics

[125 I]epibatidine binding, 86 Rb $^{+}$ efflux, and nicotine-mediated DA release were analyzed for effect of lynx1KO within each $\alpha 6$ genotype by t-test, For the electrophysiology a Kruskal-Wallis ANOVA with post-hoc Dunn's test was used. FSCV data was analyzed using a rank-sum test. For the habituation and nicotine-mediated ambulation, a two-tailed t-test was used to make comparisons between the two groups that had the same $\alpha 6$ genotype. The AMBA data were analyzed using a Fisher's exact test to compare the high and low activity groups with the effect of lynx1 on each $\alpha 6$ genotype. The CPP data were analyzed using a paired t-test for before and after training. All error bars represent the SEM.

Acknowledgments

We thank J. Michael McIntosh (University of Utah, Salt Lake City, Utah) for providing α -CtxMII. WE thank Kenneth J. Kellar (Georgetown University, Washington DC) for providing 6-I-epibatidine. We thank Xiomara Perez (Center for Health Sciences, SRI International, Menlo Park, CA) for help with electrochemistry, Andrew Steele (Department of Biological Sciences, California State Polytechnic University, Pomona, CA) for help with automated behavior analyses, and Sreelaxmi Varkala for help with other behavioral analyses.

This research was supported by funds provided by California Tobacco-Related Diseases Research Program (<http://www.trdrp.org>), Grant 22DT-0008 to RLP, and 19KT-0032 to JMM. Additional support was provided by NIH / NIDA (<https://www.drugabuse.gov/>) grants, DA003194, DA012242, and P30-DA015663 to MJM, DA017279 to HAL, and DA019375 to

HAL and MJM, DA030396 and DA035942 to RMD, and DA033831, DA032464 to JMM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Conceptualization: Rell L. Parker, Ryan M. Drenan, Michael J. Marks, Julie M. Miwa, Sharon R. Grady, Henry A. Lester.

Data curation: Rell L. Parker, Michael J. Marks, Sharon R. Grady.

Formal analysis: Rell L. Parker, Heidi C. O'Neill, Beverley M. Henley, Michael J. Marks, Sharon R. Grady, Henry A. Lester.

Funding acquisition: Rell L. Parker, Ryan M. Drenan, Julie M. Miwa.

Investigation: Rell L. Parker, Heidi C. O'Neill, Beverley M. Henley, Charles R. Wageman, Ryan M. Drenan, Michael J. Marks, Julie M. Miwa, Sharon R. Grady.

Methodology: Rell L. Parker, Heidi C. O'Neill, Ryan M. Drenan, Michael J. Marks, Julie M. Miwa, Sharon R. Grady, Henry A. Lester.

Project administration: Henry A. Lester.

Resources: Ryan M. Drenan, Henry A. Lester.

Supervision: Henry A. Lester.

Visualization: Henry A. Lester.

Writing – original draft: Rell L. Parker, Heidi C. O'Neill, Beverley M. Henley, Ryan M. Drenan, Michael J. Marks, Julie M. Miwa, Sharon R. Grady, Henry A. Lester.

Writing – review & editing: Rell L. Parker, Heidi C. O'Neill, Ryan M. Drenan, Michael J. Marks, Julie M. Miwa, Sharon R. Grady, Henry A. Lester.

References

1. Quik M, Perez XA, Grady SR. Role of $\alpha 6$ nicotinic receptors in CNS dopaminergic function: Relevance to addiction and neurological disorders. *Biochem Pharmacol*. 2011. <https://doi.org/10.1016/j.bcp.2011.06.001> PMID: 21684266.
2. Brunzell DH. Preclinical Evidence That Activation of Mesolimbic $\alpha 6$ Subunit Containing Nicotinic Acetylcholine Receptors Supports Nicotine Addiction Phenotype. *Nicotine & Tobacco Research*. 2012; 14(11):1258–69. <https://doi.org/10.1093/ntr/nts089> PMID: 22492084; PubMed Central PMCID: PMC3482009.
3. Jackson KJ, McIntosh JM, Brunzell DH, Sanjakdar SS, Damaj MI. The Role of $\alpha 6$ -Containing Nicotinic Acetylcholine Receptors in Nicotine Reward and Withdrawal. *J Pharmacol Exp Ther*. 2009; 331(2):547–54. <https://doi.org/10.1124/jpet.109.155457> PMID: 19644040
4. Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, et al. Crucial role of $\alpha 4$ and $\alpha 6$ nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. *J Neurosci*. 2008; 28(47):12318–27. <https://doi.org/10.1523/JNEUROSCI.3918-08.2008> PMID: 19020025.
5. Sanjakdar SS, Maldoon PP, Marks MJ, Brunzell DH, Maskos U, McIntosh JM, et al. Differential roles of $\alpha 6\beta 2^*$ and $\alpha 4\beta 2^*$ neuronal nicotinic receptors in nicotine- and cocaine-conditioned reward in mice. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2015; 40(2):350–60. Epub 2014/07/19. <https://doi.org/10.1038/npp.2014.177> PMID: 25035086; PubMed Central PMCID: PMC4443947.
6. Mackey ED, Engle SE, Kim MR, O'Neill HC, Wageman CR, Patzlaff NE, et al. $\alpha 6^*$ Nicotinic Acetylcholine Receptor Expression and Function in a Visual Salience Circuit. *J neurosci*. 2012; 32(30):10226–37. Epub 2012/07/28. <https://doi.org/10.1523/JNEUROSCI.0007-12.2012> PMID: 22836257.

7. Grady SR, Salminen O, Lavery DC, Whiteaker P, McIntosh JM, Collins AC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. *Biochem Pharmacol*. 2007; 74(8):1235–46. <https://doi.org/10.1016/j.bcp.2007.07.032> PMID: 17825262.
8. Whiteaker P, McIntosh JM, Luo S, Collins AC, Marks MJ. 125 I- α -conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. *Mol Pharmacol*. 2000; 57(5):913–25. PMID: 10779374.
9. Shih PY, Engle SE, Oh G, Deshpande P, Puskar NL, Lester HA, et al. Differential expression and function of nicotinic acetylcholine receptors in subdivisions of medial habenula. *J Neurosci*. 2014; 34(29):9789–802. Epub 2014/07/18. <https://doi.org/10.1523/JNEUROSCI.0476-14.2014> PMID: 25031416; PubMed Central PMCID: PMC4099552.
10. Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ. $\alpha 6$ -Containing Nicotinic Acetylcholine Receptors Dominate the Nicotine Control of Dopamine Neurotransmission in Nucleus Accumbens. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2008; 33:2158–66. <https://doi.org/10.1038/sj.npp.1301617> PMID: 18033235.
11. Ibanez-Tallon I, Miwa JM, Wang HL, Adams NC, Crabtree GW, Sine SM, et al. Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1. *Neuron*. 2002; 33(6):893–903. [https://doi.org/10.1016/S0896-6273\(02\)00632-3](https://doi.org/10.1016/S0896-6273(02)00632-3) PMID: 11906696.
12. Miwa JM, Ibanez-Tallon I, Crabtree GW, Sanchez R, Sali A, Role LW, et al. lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. *Neuron*. 1999; 23(1):105–14. [https://doi.org/10.1016/S0896-6273\(00\)80757-6](https://doi.org/10.1016/S0896-6273(00)80757-6) PMID: 10402197.
13. Miwa JM, Stevens TR, King SL, Caldaroni BJ, Ibanez-Tallon I, Xiao C, et al. The Prototoxin lynx1 Acts on Nicotinic Acetylcholine Receptors to Balance Neuronal Activity and Survival In Vivo. *Neuron*. 2006; 51(5):587–600. <https://doi.org/10.1016/j.neuron.2006.07.025> PMID: 16950157.
14. Lyukmanova EN, Shenkarev ZO, Shulepko MA, Mineev KS, D'Hoedt D, Kasheverov IE, et al. NMR structure and action on nicotinic acetylcholine receptors of water-soluble domain of human lynx1. *J Biol Chem*. 2011; 288:15888–99. <https://doi.org/10.1074/jbc.M112.436576> PMID: 21252236.
15. Lyukmanova EN, Shulepko MA, Buldakova SL, Kasheverov IE, Shenkarev ZO, Reshetnikov RV, et al. Water-soluble LYNX1 residues important for interaction with muscle-type and/or neuronal nicotinic receptors. *J Biol Chem*. 2013; 288(22):15888–99. <https://doi.org/10.1074/jbc.M112.436576> PMID: 23585571; PubMed Central PMCID: PMC3668745.
16. George AA, Bloy A, Miwa JM, Lindstrom JM, Lukas RJ, Whiteaker P. Isoform-specific mechanisms of $\alpha 3\beta 4^*$ -nicotinic acetylcholine receptor modulation by the prototoxin lynx1. *FASEB J*. 2017; 31(4):1398–420. <https://doi.org/10.1096/fj.201600733R> PMID: 28100642; PubMed Central PMCID: PMC5349798.
17. Nichols WA, Henderson BJ, Yu C, Parker RL, Richards CI, Lester HA, et al. Lynx1 Shifts $\alpha 4\beta 2$ Nicotinic Receptor Subunit Stoichiometry by Affecting Assembly in the Endoplasmic Reticulum. *J Biol Chem*. 2014; 289(45):31423–32. Epub 2014/09/07. <https://doi.org/10.1074/jbc.M114.573667> PMID: 25193667; PubMed Central PMCID: PMC4223341.
18. Morishita H, Miwa J, Heintz N, Hensch T. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. *Science*. 2010; 330:1238–40. <https://doi.org/10.1126/science.1195320> PMID: 21071629
19. Sajo M, Ellis-Davies G, Morishita H. Lynx1 Limits Dendritic Spine Turnover in the Adult Visual Cortex. *J Neurosci*. 2016; 36(36):9472–8. <https://doi.org/10.1523/JNEUROSCI.0580-16.2016> PMID: 27605620; PubMed Central PMCID: PMC5013192.
20. Thomsen MS, Arvaniti M, Jensen MM, Shulepko MA, Dolgikh DA, Pinborg LH, et al. Lynx1 and Abeta1-42 bind competitively to multiple nicotinic acetylcholine receptor subtypes. *Neurobiology of aging*. 2016; 46:13–21. Epub 2016/07/28. <https://doi.org/10.1016/j.neurobiolaging.2016.06.009> PMID: 27460145.
21. Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney SR, Miwa J, et al. In Vivo Activation of Midbrain Dopamine Neurons via Sensitized, High-Affinity $\alpha 6^*$ Nicotinic Acetylcholine Receptors. *Neuron*. 2008; 60:123–36. <https://doi.org/10.1016/j.neuron.2008.09.009> PMID: 18940593
22. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation of $\alpha 4^*$ receptors: sufficient for reward, tolerance and sensitization. *Science*. 2004; 306(5698):1029–32. <https://doi.org/10.1126/science.1099420> PMID: 15528443.
23. Drenan RM, Lester HA. Insights into the Neurobiology of the Nicotinic Cholinergic System and Nicotine Addiction from Mice Expressing Nicotinic Receptors Harboring Gain-of-Function Mutations. *Pharmacol Rev*. 2012. Epub 2012/08/14. <https://doi.org/10.1124/pr.111.004671> PMID: 22885704.
24. Labarca C, Schwarz J, Deshpande P, Schwarz S, Nowak MW, Fonck C, et al. Point mutant mice with hypersensitive $\alpha 4$ nicotinic receptors show dopaminergic deficits and increased anxiety. *Proc Natl Acad Sci U S A*. 2001; 98(5):2786–91. <https://doi.org/10.1073/pnas.041582598> PMID: 11226318.

25. Wang Y, Lee J-W, Oh G, Grady SR, McIntosh JM, Brunzell DH, et al. Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function $\alpha 6^*$ nAChRs. *Journal of Neurochemistry*. 2013; 129(2):315–27. Epub 2013 Dec 13. <https://doi.org/10.1111/jnc.12616> PMID: 24266758
26. Powers MS, Broderick HJ, Drenan RM, Chester JA. Nicotinic acetylcholine receptors containing $\alpha 6$ subunits contribute to alcohol reward-related behaviours. *Genes, brain, and behavior*. 2013:n/a-n/a. <https://doi.org/10.1111/gbb.12042> PMID: 23594044
27. Drenan RM, Grady SR, Steele AD, McKinney S, Patzlaff NE, McIntosh JM, et al. Cholinergic modulation of locomotion and striatal dopamine release is mediated by $\alpha 6\alpha 4^*$ nicotinic acetylcholine receptors. *J Neurosci*. 2010; 30(29):9877–89. <https://doi.org/10.1523/JNEUROSCI.2056-10.2010> PMID: 20660270.
28. Bordia T, McGregor M, McIntosh JM, Drenan RM, Quik M. Evidence for a role for $\alpha 6^*$ nAChRs in l-dopa-induced dyskinesias using Parkinsonian $\alpha 6^*$ nAChR gain-of-function mice. *Neuroscience*. 2015; 295:187–97. Epub 2015/03/31. <https://doi.org/10.1016/j.neuroscience.2015.03.040> PMID: 25813704; PubMed Central PMCID: PMC4408268.
29. Kuryatov A, Olale F, Cooper J, Choi C, Lindstrom J. Human $\alpha 6$ AChR subtypes: subunit composition, assembly, and pharmacological responses. *Neuropharmacology*. 2000; 39(13):2570–90. PMID: 11044728.
30. Drenan RM, Nashmi R, Imoukhuede PI, Just H, McKinney S, Lester HA. Subcellular Trafficking, Pentameric Assembly and Subunit Stoichiometry of Neuronal Nicotinic ACh Receptors Containing Fluorescently-Labeled $\alpha 6$ and $\beta 3$ Subunits. *Mol Pharmacol*. 2008; 73:27–41. <https://doi.org/10.1124/mol.107.039180> PMID: 17932221.
31. Letchworth SR, Whiteaker P. Progress and challenges in the study of $\alpha 6$ -containing nicotinic acetylcholine receptors. *Biochem Pharmacol*. 2011; 82(8):862–72. <https://doi.org/10.1016/j.bcp.2011.06.022> PMID: 21736871
32. Xiao C, Srinivasan R, Drenan RM, Mackey ED, McIntosh JM, Lester HA. Characterizing functional $\alpha 6\beta 2$ nicotinic acetylcholine receptors in vitro: mutant $\beta 2$ subunits improve membrane expression, and fluorescent proteins reveal responsive cells. *Biochem Pharmacol*. 2011; 82(8):852–61. <https://doi.org/10.1016/j.bcp.2011.05.005> PMID: 21609715.
33. Henderson BJ, Srinivasan R, Nichols WA, Dilworth CN, Gutierrez DF, Mackey ED, et al. Nicotine exploits a COPI-mediated process for chaperone-mediated up-regulation of its receptors. *The Journal of general physiology*. 2014; 143(1):51–66. Epub 2014/01/01. <https://doi.org/10.1085/jgp.201311102> PMID: 24378908; PubMed Central PMCID: PMC3874574.
34. Matta JA, Gu S, Davini WB, Lord B, Siuda ER, Harrington AW, et al. NACHO Mediates Nicotinic Acetylcholine Receptor Function throughout the Brain. *Cell reports*. 2017; 19(4):688–96. Epub 2017/04/27. <https://doi.org/10.1016/j.celrep.2017.04.008> PMID: 28445721.
35. Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, et al. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area $\alpha 6\beta 2^*$ receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. *J Neurosci*. 2010; 30(15):5311–25. <https://doi.org/10.1523/JNEUROSCI.5095-09.2010> PMID: 20392953.
36. Cohen BN, Mackey ED, Grady SR, McKinney S, Patzlaff NE, Wageman CR, et al. Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior. *Neuroscience*. 2012; 200:31–41. Epub 2011/11/15. <https://doi.org/10.1016/j.neuroscience.2011.10.047> PMID: 22079576; PubMed Central PMCID: PMC3249511.
37. Wall T. Effects of TI-299423 on Neuronal Nicotinic Acetylcholine Receptors: California Institute of Technology; 2015 <https://doi.org/10.7907/Z9JD4TQ5> <http://resolver.caltech.edu/CaltechTHESIS:03262015-100311493>.
38. Wu M, Puddifoot CA, Taylor P, Joiner WJ. Mechanisms of inhibition and potentiation of $\alpha 4\beta 2$ nicotinic acetylcholine receptors by members of the Ly6 protein family. *J Biol Chem*. 2015; 290(40):24509–18. Epub 2015/08/16. <https://doi.org/10.1074/jbc.M115.647248> PMID: 26276394; PubMed Central PMCID: PMC4591831.
39. Champiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C, et al. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. *J Neurosci*. 2003; 23(21):7820–9. PMID: 12944511.
40. Grady SR, Moretti M, Zoli M, Marks MJ, Zanardi A, Pucci L, et al. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the $\alpha 3\beta 4^*$ and $\alpha 3\beta 3\beta 4^*$ subtypes mediate acetylcholine release. *J Neurosci*. 2009; 29(7):2272–82. <https://doi.org/10.1523/JNEUROSCI.5121-08.2009> PMID: 19228980.
41. Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, et al. Chronic nicotine cell specifically upregulates functional $\alpha 4^*$ nicotinic receptors: basis for both tolerance in midbrain and

- p>enhanced long-term potentiation in perforant path.
- J Neurosci*
- . 2007; 27(31):8202–18.
- <https://doi.org/10.1523/JNEUROSCI.2199-07.2007>
- PMID: 17670967.
42. Henley BM, Williams BA, Srinivasan R, Cohen BN, Xiao C, Mackey ED, et al. Transcriptional regulation by nicotine in dopaminergic neurons. *Biochem Pharmacol*. 2013; 86(8):1074–83. Epub 2013/08/14. <https://doi.org/10.1016/j.bcp.2013.07.031> PMID: 23939186.
43. Watkins S. Cryosectioning. *Current protocols in cytometry* / editorial board, J Paul Robinson, managing editor [et al]. 2009;Chapter 12:Unit 12 5. Epub 2009/04/03. <https://doi.org/10.1002/0471142956.cy1215s48> PMID: 19340807.
44. Ramskold D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. *Nature biotechnology*. 2012; 30(8):777–82. <https://doi.org/10.1038/nbt.2282> PMID: 22820318; PubMed Central PMCID: PMC3467340.
45. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nature protocols*. 2012; 7(3):562–78. <https://doi.org/10.1038/nprot.2012.016> PMID: 22383036; PubMed Central PMCID: PMC3334321.
46. Marks MJ, Meinerz NM, Drago J, Collins AC. Gene targeting demonstrates that $\alpha 4$ nicotinic acetylcholine receptor subunits contribute to expression of diverse [3 H]epibatidine binding sites and components of biphasic 86 Rb $^+$ efflux with high and low sensitivity to stimulation by acetylcholine. *Neuropharmacology*. 2007; 53(3):390–405. <https://doi.org/10.1016/j.neuropharm.2007.05.021> PMID: 17631923.
47. Marks MJ, McClure-Begley TD, Whiteaker P, Salminen O, Brown RW, Cooper J, et al. Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. *The Journal of pharmacology and experimental therapeutics*. 2011; 337(1):187–200. Epub 2011/01/14. <https://doi.org/10.1124/jpet.110.178236> PMID: 21228066; PubMed Central PMCID: PMC3063733.
48. Baddick CG, Marks MJ. An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants. *Biochem Pharmacol*. 2011; 82(8):828–41. Epub 2011/05/18. <https://doi.org/10.1016/j.bcp.2011.04.019> PMID: 21575611; PubMed Central PMCID: PMC3162045.
49. Perez XA, Parameswaran N, Huang LZ, O'Leary KT, Quik M. Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates. *Journal of Neurochemistry*. 2008; 105(5):1861–72. <https://doi.org/10.1111/j.1471-4159.2008.05268.x> PMID: 18248617
50. Perez XA, McIntosh JM, Quik M. Long-term nicotine treatment down-regulates $\alpha 6\beta 2^*$ nicotinic receptor expression and function in nucleus accumbens. *Journal of Neurochemistry*. 2013; 127(6):762–71. <https://doi.org/10.1111/jnc.12442> PMID: 23992036
51. Steele AD, Jackson WS, King OD, Lindquist S. The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. *Proc Natl Acad Sci U S A*. 2007; 104(6):1983–8. <https://doi.org/10.1073/pnas.0610779104> PMID: 17261803; PubMed Central PMCID: PMCPMC1794260.